MARCH 30 - APRIL 1, 2023

GRAND WALKERHILL HOTEL,
SEOUL, KOREA

www.icksh.org

PROGRAM BOOK

The Korean Society of Hematology

CONTENTS

WELCOME MESSAGE

Dear Colleagues and Friends,

On behalf of the organizing committee, it is our great pleasure to invite you to participate in the 2023 Korean Society of Hematology (KSH) International Conference & 64th Annual Meeting, hosted by KSH, from March 30 to April 1, 2023.

Held every year since 2018, the ICKSH congress shares up-to-date information and provides a unique opportunity for world class leaders in the field to debate vital and contentious issues in Hematology.

Finally, after two years of the COVID-19, ICKSH 2023 is prepared as a face-to-face meeting and, of course, a virtual meeting for participants who are physically unable to attend.

Our programs will include topics such as benign hematologic diseases, various types of hematologic malignancies, coagulation/thrombosis related disorders and transfusion medicine through plenary lectures, as well as scientific and educational sessions.

In addition, a variety of stimulating social programs has been planned so participants can enjoy the fascinating Korean culture and share our warm spirit of friendship. We are preparing a memorial exhibition of the 65th Anniversary of the Korean Society of Hematology this year as well.

We welcome your support and look forward to seeing you at ICKSH 2023 in Seoul, Korea!



Cheol-Ju Yoo, MD., Ph.D.
Congress Chair
The Korean Society of Hematology

Seongsoo Jang, MD., Ph.D.
President
The Korean Society of Hematology

ICKSH2023 ORGANIZING COMMITTEE

Congress Chair
Cheol-Ju Yoo
Yonsei University College of Medicine

President
Seongsoo Jang
University of Ulsan College of Medicine

Auditor
Deog Yeon Jo
Chungnam National University College of Medicine

Auditor
Kyoo Hyung Lee
University of Ulsan College of Medicine

Secretary-General
Seok Jin Kim
Sungkyunkwan University School of Medicine

Vice Secretary-General
Hyery Kim
University of Ulsan College of Medicine

Director of Scientific Committee
Dong Yeop Shin
Seoul National University College of Medicine

Treasurer
Yong Park
Korea University College of Medicine

Editor-in-Chief
Hee Jin Huh
Dongguk University College of Medicine

Director of Health Insurance
Sung Yong Kim
Konkuk University Department of Medicine

Director of Legislation
Yoon Hwan Chang
Seoul National University College of Medicine

Director of International Cooperation
Jae Wook Lee
College of Medicine, The Catholic University of Korea

Research Director
Hyoung Jin Kang
Seoul National University College of Medicine

Director of Social Cooperation
Ho young Yhim
Jeonbuk National University Medical School

Director of Medical Policy
Jin Seok Kim
Yonsei University College of Medicine

Director of Public Relations
Jihyang Lim
College of Medicine, The Catholic University of Korea

Director of Education
Hyo Jung Kim
Hallym University College of Medicine

Director of Membership
Seong Hyun Jeong
Ajou Universitry School of Medicine

ICKSH2023 ORGANIZING COMMITTEE

Director of Textbook

Sung Hyun Kim
Dong-A University College of Medicine

Director of Medical Information

Joon Ho Moon
Kyungpook National University School of Medicine

Special Director

In-Suk Kim
Pusan National University School of Medicine

Director of Society Cooperation

Jae Sook Ahn
Chonnam National University Medical School

Special Director

Byung Sik Cho
College of Medicine, The Catholic University of Korea

ICKSH2023 EXECUTIVE STEERING COMMITTEE

Congress Chair
Chul-Ju Yoo
Yonsei University College of Medicine

President
Seongsoo Jang
University of Ulsan College of Medicine

Secretary-General
Seok Jin Kim
Sungkyunkwan University School of Medicine

Vice Secretary-General
Hyery Kim
University of Ulsan College of Medicine

Scientific Program Committee Chair
Dong Yeop Shin
Seoul National University College of Medicine

Scientific Program Committee Vice-chair
Yoon Seok Choi
Ajou University School of Medicine

Finance Committee Chair
Yong Park
Korea University College of Medicine

International Cooperation Committee Chair
Jae Wook Lee
College of Medicine, The Catholic University of Korea

Public Relations Committee Chair
Jihyang Lim
College of Medicine, The Catholic University of Korea

Public Relations Committee Vice-chair
Hee Sue Park
Chungbuk National University College of Medicine

PROGRAM AT A GLANCE Thursday, March 30, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
08:00-09:00	Registration			
08:50-09:00	Opening Remark			
09:00-10:15	**CS01** Innovative diagnostic technologies	**SS01** Challenging issues in childhood blood disorders	**SS02** How far has cell therapy developed in Hodgkin lymphoma?	**ES01** Different treatment goals for overcoming resistance or functional cure in CML
	Accelerate breakthroughs in hematology with single cell sequencing (Geoffrey McDermott, USA)	How to diagnosis and treat neutropenia in childhood (Kelly Walkovich, USA)	Pathogenesis of Hodgkin lymphoma (Ralf Küppers, Germany)	Asciminib: the first-in-class allosteric inhibitor of BCR/ABL1 kinase (Eun-Ji Choi, Korea)
	AI technology in the fi eld of blood disease (Tabe Yoko, Japan)	Updates in the treatment of pediatric relapsed/refractory acute myeloid leukemia (Keon Hee Yoo, Korea)	Emerging cellular therapy in Hodgkin lymphoma (Natalie S Grover, USA)	Treatment after failure of frontline therapy of CML-CP including allo-HSCT (Jieun Uhm, Korea)
	Discover the unique power of using droplet digital PCR (ddPCR) for hematology-oncology applications (Gina Sun, USA)			
	Holotomography and artificial intelligence: label-free 3D imaging, classification, and inference (Yongkeun Park, Korea)	Use of chimeric antigen receptor (CAR) expressing T cells for acute lymphoblastic leukemia (ALL) (Michael Verneris, USA)	Novel treatment of relapsed/refractory Hodgkin lymphoma (Hyeon-Seok Eom, Korea)	Update on treatment free remission (Jae Joon Han, Korea)
10:15-10:30	Break			

PROGRAM AT A GLANCE Thursday, March 30, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
10:30-11:15	**PL01** Regulation of iron metabolism (Martina U. Muckenthaler, Germany)			
11:15-12:00	**PS01** What can Nano do for Medicine? (Taeghwan Hyeon, Korea)			
12:00-12:15	Break			
12:15-13:05	**SY01** Satellite Symposium 01 - CML NOVARTIS ASCIMINIB, new paradigm treatment option in CML for patients who were previously treated with 2 or more TKIs (Andreas Hocchaus, Germany)	**SY02** Satellite Symposium 02 - DLBCL Roche Unmet need in 1L DLBCL and POLARIX trial (Georg Lenz, Germany)	**SY03** Satellite Symposium 03 - MM Bristol Myers Squibb Celgene | A Bristol Myers Squibb Company Maintenance treatment post autotransplant for multiple myeloma (Kevin Song, Canada)	
13:05-13:20	Break			
13:20-14:50	Young Investigator Presentation	**OP01** Acute myeloid leukemia	**OP02** Lymphoma	**OP03** Stem cell transplant and laboratory hematology
14:50-15:05	Break			

PROGRAM AT A GLANCE Thursday, March 30, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
15:05-16:20	**JS01** Asian Hematology Session I (JSM & KMMWP) - Multiple Myeloma	**SS03** Where we are, in the era of new agents for aplastic anemia?	**SS04** How can we approach thrombocytopenia?	**ES02** How I treat rare lymphomas?
	POEMS syndrome: advances in molecular pathophysiology and treatment (Chiaki Nakaseko, Japan)	Aplastic Anemia: Current management considerations (Emma M. Groarke, USA)	Diagnosis and treatment of TA-TMA; Current challenge and future strategies (Sandro Rossetti, USA)	Prognostic factors in intravascular large B-cell lymphoma: A comprehensive review (Youngwoo Jeon, Korea)
	Updates on POEMS syndrome in Korea (Jin Seok Kim, Korea)	Clinical and molecular factors of clonal evolution in aplastic anemia (Jaroslaw P. Maciejewski, USA)	Genetics of inherited thrombocytopenia (Kathleen Freson, Belgium)	T-large granular lymphocytic leukemia (Jae-Cheol Jo, Korea)
	Therapeutic approach of Waldenström's macroglobulinemia in Japan (Hiroshi Handa, Japan)			
	Clinical researches on Waldenström's macroglobulinemia in Korea (Hosup Lee, Korea)	Non-transplant therapy for pediatric aplastic anemia (Jae Wook Lee, Korea)	Advances on pathogenesis and diagnosis of TTP (Hyun Kyung Kim, Korea)	Lymphomatoid granulomatosis (Jeong-Ok Lee, Korea)
16:20-16:35	Break			

PROGRAM AT A GLANCE Thursday, March 30, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
16:35-17:50	**CS02** Innovative therapeutic technologies	**SS05** Artificial intelligence application in hematology	**SS06** Defining and improving survival of high-risk multiple myeloma	**ES03** Rare hematologic malignancies with cutaneous manifestation
	A Phase 1a Study of BR101801, PI3Kγδ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies (Bong-Seog Kim, Korea)	Artificial intelligence in hematology: basic concepts (Roni Shouval, USA)	Identification of high-risk multiple myeloma (Niels van de Donk, The Netherlands)	Sezary syndrome and mycosis fungoides (Hyewon Lee, Korea)
	The gut microbiome as a novel predictive biomarker and therapeutic target in lymphoma patients (Woorim Kang, Korea)	How machine learning deepens our understanding of hematologic malignancies (Valeria Visconte, USA)	Updated diagnosis and treatment of plasma cell leukemia (Sung-Hoon Jung, Korea)	Systemic mastocytosis (Hyun Jung Lee, Korea)
	Bispecific antibody : ABL Bio (Jonghwa Won, Korea)			
	KF1601, a novel orally bioavailable inhibitor of Bcr-Abl T315I, without thrombotic microangiopathy (Sung-Min Ahn, Korea)	Pitfalls of AI for medical application (Jongmun Choi, Korea)	Safety and efficacy of locally produced novel BCMA CART cells for relapsed/refractory multiple myeloma and AL amyloidosis (Moshe Gatt, Israel)	Plasmacytoid dendritic cell neoplasm (Yoo Jin Lee, Korea)
17:50-18:30	Break			
18:10-19:30	Welcome Reception (VISTA Hall Lobby)			

PROGRAM AT A GLANCE Friday, March 31, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
08:00-09:00	Registration			
09:00-10:15	**JS02** ASH-KSH Joint Symposium - T Cell Lymphoma	**SS07** What is the direction of the new CAR-T therapy?	**SS08** Comprehensive approaches to understand hemophilia	**ES04** Back to the basic: transfusion support
	NK cells: next generation cell therapies for cancer (Katy Rezvani, USA)	Engineering next-generation T cells for cancer immunotherapy (Yvonne Chen, USA)	Genotyping of hemophilia, why we need it and how we do? (Jill Johnsen, USA)	Transfusion support for HSCT (Dong Wook Jekarl, Korea)
	Treatment of extranodal NK/T-cell lymphoma: Korean Lymphoma Working Party experience (Seok Jin Kim, Korea)	Development of CAR-T therapy for acute lymphoblastic leukemia (Hyoung Jin Kang, Korea)	Value of national cohort registry data of hemophilia (Jung Woo Han, Korea)	Evidence based transfusion threshold (Dae-Hyun Ko, Korea)
	CAR-T for the treatment of T cell malignancies (John DiPersio, USA)			
	Treatment of peripheral T-cell lymphoma: Korean Lymphoma Working Party experience (Deok-Hwan Yang, Korea)	Updates on the latest developments in CAR-T therapies (Hiroshi Fujiwara, Japan)	Essentials of laboratory issues in Emicizumab (Sang Hyuk Park, Korea)	Current status of manufactured blood cells (Eun Jung Baek, Korea)
10:15-10:30	Break			

PROGRAM AT A GLANCE Friday, March 31, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
10:30-11:15	**PL02** The role of the intestinal microbiome in cancer immunotherapy (Marcel van den Brink, USA)			
11:15-12:00	Poster Viewing (Walker Hall)			
12:00-12:15	Break			
12:15-13:05	**SY04** Satellite Symposium 04 - AA KYOWA KIRIN Recent advances in the pathogenesis and treatment of aplastic anemia (Kohei Hosokawa, Japan)	**SY05** Satellite Symposium 05 - AML HANDOK Value of intensive therapy in high-risk AML (Martin Bornhaeuser, Germany)	**SY06** Satellite Symposium 06 - CLL janssen When and whom to start treatment of CLL patients and how to optimally manage CLL patients with Imbruvica (Ghia Paolo, Italy)	
13:20-14:50	**OP04** Acute leukemia and quality of life	**OP05** Bone marrow failure syndrome and myeloproliferative neoplasm	**OP06** Multiple myeloma	**OP07** Anemia, bleeding and platelet
14:50-15:05	Break			

PROGRAM AT A GLANCE Friday, March 31, 2023

<table>
<tr><th>TIME</th><th>ROOM 1</th><th>ROOM 2</th><th>ROOM 3</th><th>ROOM 4</th></tr>
<tr><td rowspan="5">15:05-
16:20</td><td>JS03
EHA-KSH Joint Symposium
- Myelodysplastic Syndrome</td><td>SS09
Which immune therapy is our future weapon against AML?</td><td>SS10
Next-generation molecular genomic and cytogenomic technology in hematology</td><td>ES05
Practical issues in CAR-T
KOR</td></tr>
<tr><td>Novel approaches in MDS
(Uwe Platzbecker, Germany)</td><td rowspan="2">Immune checkpoint inhibition for AML ; CD47 blockade and beyond
(Naval Daver, USA)</td><td rowspan="2">A transcriptomic approach to clinical diagnosis, prognosis and therapy selection in AML
(Aly Karsan, Canada)</td><td rowspan="2">Setting up the facility for CAR T cell therapy
(Ja Min Byun, Korea)</td></tr>
<tr><td>Treatment of MDS: Korean AML/MDS working party experience
(June-Won Cheong, Korea)</td></tr>
<tr><td>Standard management of MDS
(Lionel Adès, France)</td><td rowspan="2">Determining the barriers to successful CAR T cell therapy for AML
(Miriam Y Kim, USA)</td><td rowspan="2">Whole genome sequencing of fluorescence in situ hybridized cells in hematologic malignancies using SLACS
(Sunghoon Kwon, Korea)</td><td rowspan="2">Technical aspect of manufacturing CAR T cell product
(Jong-Seo Lee, Korea)</td></tr>
<tr><td>Genetic alterations in myelodysplastic neoplasms
(Yoo-Jin Kim, Korea)</td><td>Adoptive T cell transfer of three universal tumor associated antigens-specific T cells for the treatment of AML
(Byung Sik Cho, Korea)</td><td>Next generation cytogenetics – optical mapping for comprehensive structural variant detection in hematological malignancies and beyond
(Alexander Hoischen, The Netherlands)</td><td>Managing adverse events of CAR T cell therapy
(Jae Won Yoo, Korea)</td></tr>
<tr><td>16:20-
16:35</td><td colspan="4">Break</td></tr>
</table>

PROGRAM AT A GLANCE Friday, March 31, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
16:35-17:50		**JS04** International Collaborative Session - Aplastic anemia	**SS11** Liquid biopsy application in hematology	**SS12** Up-to-date diagnostic and treatment strategies of adult ALL patients
		Overview of AA diagnosis and treatment in NIHBT, Vietnam (Nguyen Thi Thao, Vietnam)	Cell-free DNA profiling for monitoring of complications of hematopoietic cell transplantation (Iwijn De Vlaminck, USA)	Are we moving towards a chemo- and transplant-free management of Ph-positive adult ALL? (Robin Foa, Italy)
		The incidence and real-world outcome of aplastic anemia in Thailand (Lalita Norasetthada, Thailand)	Towards non-invasive monitoring of disease and microbe invasion in patients with hematologic malignancies (Charles Gawad, USA)	Development of more-effective CAR T-cell therapy for ALL (Saar I Gill, USA)
		Role of TPO receptor agonists in aplastic anemia treatment (Jun Ho Jang, Korea)	Clinical applications of circulating tumor DNA analysis in lymphoma (Seung-Tae Lee, Korea)	Overcoming high-risk features in adult ALL patients (Jae-Ho Yoon, Korea)
17:50-18:30	Break			
18:10-18:40	Cocktail Reception (Vista 3)			
18:40-20:00	Gala dinner (Vista 1+2)			

PROGRAM AT A GLANCE Saturday, April 1, 2023

TIME	ROOM 1	ROOM 2	ROOM 3	ROOM 4
07:30-08:30				Business Meeting
08:30-09:00	Working party Report			
09:00-10:15	**JS05** Asian Hematology Session II - Red Blood Cell Disorder	**SS13** Current knowledge of human hematopoietic stem cell	**SS14** What's new in chronic lymphocytic leukemia?	**ES06** Novel therapeutics for myeloproliferative neoplasms
	Overview of thalassaemia and hemoglobinopathies in Bangladesh (Mahmood A. Chowdhury, Bangladesh)	Single cell HSPC map (William J. Greenleaf, USA)	Translating scientific advances in CLL (Richard Rosenquist, Sweden)	Prognostication in MPNs (including mutation abnormalities) (Junshik Hong, Korea)
	Current situation of thalassemia care in Cambodia (Chean Sophâl, Cambodia)	Humanized mouse and non-human primate: Animal models for hematopoietic stem cell research (Kyung-Rok Yu, Korea)	Patient selection for time limited versus continued therapy (Jennifer R. Brown, USA)	Novel therapeutics for MF (including cyotpenic myelofibrosis) (Sung-Eun Lee, Korea)
	Epidemiology and diagnosis of hemolytic anemia in Korea (Heewon Chueh, Korea)	What we know about HSC homing? (Xinxin Huang, China)	MRD monitoring in CLL Patients (Ki-Seong Eom, Korea)	Novel therapeutics for ET/PV (Seugyun Yoon, Korea)
10:15-10:30	Break			
10:30-11:15	**PL03** Recent advance in the hematopoietic stem cell research (Toshio Suda, Singapore)			
11:15-11:30	Break			
11:30-12:00	Award Ceremony & Closing			

FLOOR PLAN

1F



Room 4
- Educational Session
- Business Meeting(April 1)

Posters

B1



Room 3
- Scientific Session

Ida Lobby
- Kit & Cloak Desk
- Event Desk

Ida 2
- Preview Room

Grand Hall Lobby
- Exhibition
- Coffee Break
- Internet Lounge

65th Anniversary Hall
- Memorial Exhibition of KSH
- Event & Photo Zone
- Coffee & Tea

FLOOR PLAN

B2



Room 1/Room 2
- Plenary Session
- Scientific Session
- Opening & Closing
- Gala Dinner (March 31)

ICKSH Secretariat

Vista Hall Lobby
- Exhibition
- Coffee Break
- Welcome Reception (March 30)

GENERAL INFORMATION

REGISTRATION

All participants are required to check in at the registration desk to pick up their name badge. Badges must be worn during all scientific sessions and social programs.

>> Location: Vista Lobby (B2)

>> Operation Hours: March 30 (Thu) 08:00 - 18:00
March 31 (Fri) 08:00 - 18:00
April 1 (Sat) 08:00 - 13:00

>> On-Site Registration Fees

Category	On-Site Registration Fees
General	USD 200
Resident/ Trainee/ Nurse/ Student	USD 100

+ Registration fees include: Participation in all scientific sessions, exhibition, satellite symposium including lunch, coffee breaks, conference kit, welcome reception and gala dinner.
+ Conference Kit will be distributed with your name badge at the Kit desk (B1). The kit includes a Program book and Abstract book.

LUNCH

Lunch boxes will be provided during the satellite symposium. Please wear your name badge.

>> Location: Room1 - Room4

>> Operation Hours: March 30(Thu) 12:00-13:00
March 31(Fri) 12:00-13:00

COFFEE BREAK

Coffee and tea will be served at coffee break times at the Vista Hall Lobby (B2) and Grand Hall Lobby (B1). Barista coffee and tea will be provided during the conference at the Grand Hall Lobby (65th Anniversary Hall of KSH) (B1).

GENERAL INFORMATION

CERTIFICATE OF ATTENDANCE

Participants may receive the certificate of attendance. Please contact the ICKSH 2023 Secretariat after conference via icksh@icksh.org.

USEFUL PHOTO NUMBERS

+ Police 112
+ Fire and ambulance 119
+ Medical Emergency 1339

USEFUL TRAVEL WEBSITE

+ Seoul City Tourism: http://www.visitseoul.net
+ Seoul Metropolitan Government: http://english.seoul.go.kr
+ Korean Tourism Organization: http://kto.visitkorea.or.kr/eng.kto

ICKSH 2023 SECRETARIAT OFFICE

+ Onsite: Registration Desk, Vista Hall Lobby (B2)
  Tel. +82-2-450-2201 (Sercretariat) +82-2-450-2202 (Registraiton) Email: icksh@icksh.org
+ After conference: 1F, Haeoreum Bldg., 16 Yeoksam-ro 17 Gil, Gangnam-gu, Seoul, 06246, Korea
  Tel. +82-2-566-6031 Fax. +82-2-566-6087 Email. icksh@icksh.org

SPEAKER INFORMATION

PREVIEW ROOM

All speakers are requested to visit the preview room no later than 2 hours before their session. They will be assisted by our staff who will help upload the presentation file to the server before the session.

>> Location: IDA 2 (B1)

>> Operation Hours: March 30 (Thu) 07:00 - 18:00
March 31 (Fri) 07:00 - 18:00
April 1 (Sat) 07:00 - 12:00

POSTER PRESENTATION

All posters are required to have a presentation time as following schedule.
After onsite reviews, the scientific committee will select Best Posters and the winners should attend the award at Closing Ceremony on April 1 (Sat).

>> Date & Time: March 31(Fri), 11:15 - 12:00

>> Location: Walker Hall (1F)

SOCIAL PROGRAM

OPENING

With the opening address by Cheol-Ju Yoo, Congress chairman, ICKSH 2023 will begin.

>> Date & Time: March 30 (Thu) 09:00

>> Location: Room1 (B2)

WELCOME RECEPTION

Welcome to ICKSH 2023! The Organizing Committee will prepare welcome reception.

>> Date & Time: March 30 (Thu) 18:10 - 19:30

>> Location: Vista Hall Lobby (B2)

GALA DINNER

Please join us to share an unforgettable evening. Enjoy the climax of ICKSH 2023 with an excellent dinner and exciting performance.

>> Date & Time: March 31 (Fri) 18:10 - 20:00 (Reception: 18:10 - 18:40)

>> Location: Vista Hall (B2)

EVENTS

KSH 65th ANNIVERSARY EVENTS

We are preparing a Memorial Exhibition for the 65th Anniversary of the Korean Society of Hematology this year. Various events and prizes await you, so visit the 65th Anniversary Hall and enjoy the programs!

>> Date & Time: March 30 (Thu) - April 1(Sat)

>> Location: 65th Anniversary Hall (B1)

LUCKY DRAW

Please participate in the KSH General Assembly and do not miss the lucky draw. (Korean participants only)

>> Date & Time: April 1 (Sat) 12:00

>> Location: Vista 1 (B2)

1 Person	1 Person	1 Person	3 Persons
			
LG Stand by me TV	Apple Watch SE (GPS, 44mm)	LG Code Zero	Sinsegae Gift Card

EVENTS

EARLY-BIRD EVENT

Daily gifts will be given to session participants each day up to 100 people on a first come, first served basis.

>> Date & Time: March 30(Thu) - April 1(Sat)

>> Location: Room1 - Room4

BOOTH STAMP EVENT

If you visit exhibition booths and complete the stamp sheet, gifts will be given.

>> Date & Time: March 30 (Thu) - April 1 (Sat)

>> Location: IDA hall Lobby (B1)

SPONSORS

DIAMOND

KYOWA KIRIN

janssen | PHARMACEUTICAL COMPANIES OF Johnson&Johnson

Bristol Myers Squibb™
Celgene | A Bristol Myers Squibb Company

Roche

HANDOK

NOVARTIS

PLATINUM

GC Pharma

AMGEN®

Takeda

astellas

SPONSORS

GOLD

Otsuka

Pfizer

MSD
INVENTING FOR LIFE

CELLTRION PHARM
CELLTRION

YUHAN

abbvie

ANTENGENE

sanofi

SILVER

Roche

AstraZeneca

SPONSORS

BRONZE

JW Pharmaceutical

sysmex

DONG-A ST

samyang

RECORDATI RARE DISEASES GROUP

DIAGENEX 디아이에넥스

IL-YANG PHARM.

bionano GENOMICS

MDxK

CLINIGEN

PharmaEssentia
Better Science . Better Lives.

BeiGene

EXHIBITION

B1

GRAND HALL



No.	Company Name
G-1	Antengene Medicine
G-2	Otsuka
G-3	Pfizer Korea
G-4	MSD KOREA
G-5	YUHAN
G-6	Abbvie
G-7	Celltrion Pharm
G-8	Sanofi-Aventis

No.	Company Name
S-1	AstraZeneca Korea
S-2	Roche Diagnostics Korea
B-1	Clinigen Korea
B-2	Bionano genomics & MDxK
B-3	Sysmex Korea
B-4	DIAGENEX
B-5	Samyang Holdings Corp.

No.	Company Name
B-6	PharmaEssentia Korea
B-7	Dong-A ST
B-8	BeiGene
B-9	Recordati Korea
B-10	JW Pharmaceutical
B-11	JW Pharmaceutical
B-12	IL-YANG PHARM

EXHIBITION

B2

VISTA HALL

No.	Company Name
D-1	Kyowakirin
D-2	Roche Korea
D-3	Celgene/BMS
D-4	Novartis Korea
D-5	Janssen Korea
D-6	Handok Inc.

No.	Company Name
P-1	Takeda Pharmaceuticals Korea
P-2	Amgen Korea
P-3	GC Biopharma
P-4	Astellas Korea

KEY SPEAKERS

MARCH 30 (Thu.)

[PL01] Plenary Lecture 01

10:30 - 11:15 | Room 1

Regulation of iron metabolism

Martina U. Muckenthaler
University of Heidelberg, Germany

[PS01] Presidential Symposium

11:15 - 12:00 | Room 1

What can Nano do for Medicine?

Taeghwan Hyeon
Seoul National University, Korea

MARCH 31 (Fri.)

[PL02] Plenary Lecture 02

10:30 - 11:15 | Room 1

The role of the intestinal microbiome in cancer immunotherapy

Marcel van den Brink
Memorial Sloan Kettering Cancer Center, USA

APRIL 1 (Sat.)

[PL03] Plenary Lecture 03

10:30 - 11:15 | Room 1

Recent advance in the hematopoietic stem cell research

Toshio Suda
National University of Singapore, Singapore

ICKSH 2023

2023 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE
& KSH 65TH ANNIVERSARY

DAILY PROGRAM

March 30 (Thursday)

March 31 (Friday)

April 1 (Saturday)

DAILY PROGRAM Thursday, March 30

08:50-09:00 **Opening Remark** Room 1

09:00-10:15 **[CS01] Innovative diagnostic technologies** Room 1

Chairs Jin-Yeong Han (Dong-A University College of Medicine, Korea)
In-Suk Kim (Pusan National University School of Medicine, Korea)

CS01-1 Accelerate breakthroughs in hematology with single cell sequencing
Geoffrey McDermott (10x Genomics, Inc., USA)

CS01-2 AI technology in the field of blood disease
Tabe Yoko (Juntendo University, Japan)

CS01-3 Discover the unique power of using droplet digital PCR (ddPCR) for hematology-oncology applications
Gina Sun (Bio-Rad Laboratories, USA)

CS01-4 Holotomography and artificial intelligence: label-free 3D imaging, classification, and inference
Yongkeun Park (Tomocube Inc., Korea)

09:00-10:15 **[SS01] Challenging issues in childhood blood disorders** Room 2

Chairs Hoon Kook (Chonnam National University Medical School, Korea)
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea)

SS01-1 How to diagnosis and treat neutropenia in childhood
Kelly Walkovich (University of Michigan, USA)

SS01-2 Updates in the treatment of pediatric relapsed/refractory acute myeloid leukemia
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)

SS01-3 Use of chimeric antigen receptor (CAR) expressing T cells for acute lymphoblastic leukemia (ALL)
Michael Verneris (Children's Hospital Colorado, USA)

DAILY PROGRAM Thursday, March 30

09:00-10:15 **[SS02] How far has cell therapy developed in Hodgkin lymphoma?** Room 3

Chairs Hyeon-Seok Eom (National Cancer Center, Korea)
Sung Yong Oh (Dong-A University College of Medicine, Korea)

SS02-1 Pathogenesis of Hodgkin lymphoma
Ralf Küppers (University of Duisburg-Essen, Germany)

SS02-2 Emerging cellular therapy in Hodgkin lymphoma
Natalie S Grover (The University of North Carolina at Chapel Hill, USA)

SS02-3 Novel treatment of relapsed/refractory Hodgkin lymphoma
Hyeon-Seok Eom (National Cancer Center, Korea)

09:00-10:15 **[ES01] Different treatment goals for overcoming resistance or functional cure in CML** Room 4

Chair Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
Hawk Kim (Gachon University College of Medicine, Korea)

ES01-1 Asciminib: the first-in-class allosteric inhibitor of BCR/ABL1 kinase
Eun-Ji Choi (University of Ulsan College of Medicine, Korea)

ES01-2 Treatment after failure of frontline therapy of CML-CP including allo-HSCT
Jieun Uhm (Hanyang University College of Medicine, Korea)

ES01-3 Update on treatment free remission
Jae Joon Han (Kyung Hee University College of Medicine, Korea)

10:15-10:30 Break

10:30-11:15 **[PL01] Plenary Lecture 01** Room 1+2

Chair Sung-Soo Yoon (Seoul National University College of Medicine, Korea)

Regulation of iron metabolism
Martina U. Muckenthaler (University of Heidelberg, Germany)

DAILY PROGRAM Thursday, March 30

11:15-12:00 **[PS01] Presidential Symposium** Room 1+2

Chair Seongsoo Jang (University of Ulsan College of Medicine, Korea)

What can Nano do for Medicine?
Taeghwan Hyeon (Seoul National University, Korea)

12:00-12:15 Break

12:15-13:05 **[SY01] Novartis** NOVARTIS Room 1

Chair Dong-Wook Kim (Eulji University School of Medicine, Korea)

ASCIMINIB, new paradigm treatment option in CML for patients who were previously treated with 2 or more TKIs
Andreas Hocchaus (Jena University Hospital, Germany)

12:15-13:05 **[SY02] Roche** Roche Room 2

Chair Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

Unmet need in 1L DLBCL and POLARIX trial
Georg Lenz (University Hospital in Münster, Germany)

12:15-13:05 **[SY03] BMS-Celgene** Bristol Myers Squibb Celgene | A Bristol Myers Squibb Company Room 3

Chair Ho Sup Lee (Kosin University College of Medicine, Korea)

Maintenance treatment post autotransplant for multiple myeloma
Kevin Song (Vancouver General Hospital, Canada)

13:05-13:20 Break

DAILY PROGRAM Thursday, March 30

13:20-14:50 **[YI] Young Investigator Presentation** Room 1

Chairs Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
Hyoung Jin Kang (Seoul National University College of Medicine, Korea)

YI-1 Identification of Clonical Significance and Appropriate Diagnostic Tools for Minimal Residual Disease in Acute Myeloid Leukemia Patients Treated with Venetoclax-Based Low-Intensity Chemotherapy
Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea)

YI-2 A study on the discovery of candidates for therapeutic targets using microRNA in T-cell lymphomas and the tracking of minimal residual disease
Youngwoo Jeon (College of Medicine, The Catholic University of Korea, Korea)

YI-3 Monitoring mutational profile and prognosis of multiple myeloma patients with multiple focal lesions in PET/CT using liquid biopsy
Hee Jeong Cho (Kyungpook National University School of Medicine, Korea)

YI-4 Development of cytotoxic T cell therapy against tumor-specific antigen discovered by artificial intelligence
Jeong Suk Koh (Chungnam National University College of Medicine, Korea)

YI-5 Establishment of clinical utility of minimal residual disease assessment using next-generation sequencing
Hye Won Kook (Yonsei University College of Medicine, Korea)

YI-6 Microbiome analysis for anticipating GVHD and predicting clinical outcome in patients received allogeneic hematopoietic stem cell transplantation
Ju Hyung Kim (Kyungpook National University School of Medicine, Korea)

YI-7 A study on machine learning models for early diagnosis of leukemia
Hyunji Kim (Seoul National University College of Medicine, Korea)

YI-8 Establishment of minimal residual disease monitoring strategy for patients B-lymphoblastic leukemia after CD19-targeted therapy and development of standardized protocols through machine learning
Ari Ahn (College of Medicine, The Catholic University of Korea, Korea)

YI-9 Establishment of bortezomib resistant multiple myeloma cell line, and analysis of antioxidant enzymes and autophagy markers
Se Won Lee (Ewha Womans University College of Medicine, Korea)

DAILY PROGRAM Thursday, March 30

13:20-14:50 **[OP01] Acute myeloid leukemia** Room 2

Chairs Joon Seong Park (Ajou University School of Medicine, Korea)
Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)

OP01-1 Prognostic value of genomic clusters using machine learning in older adults with AML
Tong Yoon Kim (College of Medicine, The Catholic University of Korea, Korea)

OP01-2 Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia in the real world
Ga-young Song (Chonnam National University Hwasun Hospital, Korea)

OP01-3 A paired outcome evaluation of wilms tumor-1 (WT-1) gene mutation and expression in acute myeloid leukemia
Pranay Tanwar (All India Institute of Medical Sciences, India)

OP01-4 CEBPA mutations in 1716 Korean patients with acute myeloid leukemia
Hoon Seok Kim (College of Medicine, The Catholic University of Korea, Korea)

OP01-5 Antileukemic effect of cyclin-dependent kinase 7 inhibitor, YPN-005 combined with FLT3 inhibitor in FMS-tyrosine kinase 3 -mutated acute myeloid leukemia
Bon-Kwan Goo (University of Ulsan College of Medicine, Korea)

OP01-6 DRP1 inhibition enhances venetoclax-induced mitochondrial apoptosis in TP53-mutated acute myeloid leukemia cells through BAX/BAK activation
June-Won Cheong (Yonsei University College of Medicine, Korea)

13:20-14:50 **[OP02] Lymphoma** Room 3

Chairs Byung-Su Kim (College of Medicine, The Catholic University of Korea, Korea)
Seong Hyun Jeong (Ajou University School of Medicine, Korea)

OP02-1 Classical Hodgkin lymphoma: Clinical features, prognostic factors, and treatment outcomes in a Malaysian tertiary centre
Wei Quan Low (Sultanah Aminah Hospital, Malaysia)

OP02-2 Phase II study of bortezomib/dexamethasone induction and maintenance therapy in relapsed/refractory cutaneous T cell lymphoma (CISL1701 study)
Yoon Seok Choi (Ajou University School of Medicine, Korea)

DAILY PROGRAM Thursday, March 30

OP02-3 Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 2 study (ELM-2) prespecified analysis results
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)

OP02-4 Novel subgroup analyses of subcutaneous epcoritamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
Young Rok Do (Keimyung University Dongsan Medical Center, Korea)

OP02-5 The treatment outcome of tisagenlecleucel for the patient with relapsed/refractory B-cell lymphoid malignancies in Samsung Medical Center
Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea)

OP02-6 How to improve clinical outcomes of tisagenlecleucel treatment in relapsed/refractory diffuse large B cell lymphoma?
Gi June Min (Seoul St. Mary's Hematology Hospital, Korea)

OP02-7 Distribution and sequential patterns of the second malignancies among the lymphoid neoplasm in South Korea
Tong Yoon Kim (College of Medicine, The Catholic University of Korea, Korea)

13:20-14:50 **[OP03] Stem cell transplant and laboratory hematology** Room 4

Chairs Young Kyung Lee (Hallym University College of Medicine, Korea)
Young-Uk Cho (University of Ulsan College of Medicine, Korea)

OP03-1 Genomic alterations in chronic myeloid leukaemia patients who failed second generation tyrosine kinase inhibitor
Siew Lian Chong (Hospital Ampang, Malaysia)

OP03-2 Genome-wide methylation profiling of BCR/ABL1-negative myeloproliferative neoplasms
Miyoung Kim (University of Ulsan College of Medicine, Korea)

OP03-3 Machine learning based predictive classifier for bone marrow failure syndrome using complete blood count and differential cell populations
Hongyul An (Genome Opinion, Korea)

DAILY PROGRAM Thursday, March 30

OP03-4 G6PD-independent differentiation of human CD34 positive haematopoietic stem and progenitor cells into mature erythrocytes
Kanyarat Boonpeng (Chulalongkorn University, Thailand)

OP03-5 LeGO vector labeling of stem cells and non-stem cells in ectopic foci formation model
Dmitriy Karpenko (National Medical Research Center for Hematology, Russia)

OP03-6 Outcome analysis and of BKPyV-associated hemorrhagic cystitis in paedriatric allogenic stem cell transplant recipients for benign hematological disorders in Pakistan
Shafaq Abdul Samad (National Institute of Blood Disease and BMT, Pakistan)

14:50-15:05 Break

15:05-16:20 **[JS01] Asian Hematology Session I (JSM & KMMWP) - Multiple myeloma** Room 1

Chairs Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
Chiaki Nakaseko (International University of Health and Welfare School of Medicine, Japan)

JS01-1 POEMS syndrome: advances in molecular pathophysiology and treatment
Chiaki Nakaseko (International University of Health and Welfare School of Medicine, Japan)

JS01-2 Updates on POEMS syndrome in Korea
Jin Seok Kim (Yonsei University College of Medicine, Korea)

JS01-3 Therapeutic approach of Waldenström's macroglobulinemia in Japan
Hiroshi Handa (Gunma University, Japan)

JS01-4 Clinical researches on Waldenström's macroglobulinemia in Korea
Hosup Lee (Kosin University College of Medicine, Korea)

DAILY PROGRAM Thursday, March 30

15:05-16:20 **[SS03] Where we are, in the era of new agents for aplastic anemia?** Room 2

Chairs Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)
Ho Joon Im (University of Ulsan College of Medicine, Korea)

SS03-1 Aplastic anemia: Current management considerations
Emma M. Groarke (National Institutes of Health, USA)

SS03-2 Clinical and molecular factors of clonal evolution in aplastic anemia
Jaroslaw P. Maciejewski (Cleveland Clinic, USA)

SS03-3 Non-transplant therapy for pediatric aplastic anemia
Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)

15:05-16:20 **[SS04] How can we approach thrombocytopenia?** Room 3

Chairs Soo-Mee Bang (Seoul National University College of Medicine, Korea)
Hyun Kyung Kim (Seoul National University College of Medicine, Korea)

SS04-1 Diagnosis and treatment of TA-TMA; Current challenge and future strategies
Sandro Rossetti (Alexion Pharmaceuticals, Inc., USA)

SS04-2 Genetics of inherited thrombocytopenia
Kathleen Freson (University of Leuven, Belgium)

SS04-3 Advances on pathogenesis and diagnosis of TTP
Hyun Kyung Kim (Seoul National University College of Medicine, Korea)

15:05-16:20 **[ES02] How I treat rare lymphomas?** Room 4

Chairs Hyo Jung Kim (Hallym University College of Medicine, Korea)
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)

ES02-1 Prognostic factors in intravascular large B-cell lymphoma: A comprehensive review
Youngwoo Jeon (College of Medicine, The Catholic University of Korea, Korea)

DAILY PROGRAM Thursday, March 30

ES02-2 T-large granular lymphocytic leukemia
Jae-Cheol Jo (University of Ulsan College of Medicine, Korea)

ES02-3 Lymphomatoid granulomatosis
Jeong-Ok Lee (Seoul National University Bundang Hospital, Korea)

16:20-16:35 Break

16:35-17:50 **[CS02] Innovative therapeutic technologies** Room 1

Chairs Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)
Yong Park (Korea University school of medicine, Korea)

CS02-1 A Phase 1a Study of BR101801, PI3Kγδ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies
Bong-Seog Kim (Boryung Co. Ltd., Korea)

CS02-2 The gut microbiome as a novel predictive biomarker and therapeutic target in lymphoma patients
Woorim Kang (CJ Bioscience Inc., Korea)

CS02-3 Bispecific antibody : ABL Bio
Jonghwa Won (ABL Bio Inc., Korea)

CS02-4 KF1601, a novel orally bioavailable inhibitor of Bcr-Abl T315I, without thrombotic microangiopathy
Sung-Min Ahn (ImmunoForge Inc., Korea)

16:35-17:50 **[SS05] Artificial intelligence application in hematology** Room 2

Chairs Mina Hur (Konkuk University School of Medicine, Korea)
Myung-Hyun Nam (Korea University School of Medicine, Korea)

SS05-1 Artificial intelligence in hematology: basic concepts
Roni Shouval (Memorial Sloan Kettering Cancer Center, USA)

DAILY PROGRAM Thursday, March 30

SS05-2 How ML deepens our understanding of hematologic malignancies?
Valeria Visconte (Cleveland Clinic, USA)

SS05-3 Pitfalls of AI for medical application
Jongmun Choi (Seegene Medical Foundation, Korea)

16:35-17:50 **[SS06] Defining and improving survival of high-risk multiple myeloma** Room 3

Chairs Chang-Ki Min College of Medicine, The Catholic University of Korea, Korea)
Jin Seok Kim (Yonsei University College of Medicine, Korea)

SS06-1 Identification of high-risk multiple myeloma
Niels van de Donk (Amsterdam University Medical Center, The Netherlands)

SS06-2 Updated diagnosis and treatment of plasma cell leukemia
Sung-Hoon Jung (Chonnam National University Hwasun Hospital, Korea)

SS06-3 Safety and efficacy of locally produced novel BCMA CART cells for relapsed/refractory multiple myeloma and al amyloidosis
Moshe Gatt (The Hebrew University of Jerusalem, Israel)

16:35-17:50 **[ES03] Rare hematologic malignancies with cutaneous manifestation** Room 4

Chairs Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea)
Jae-Sook Ahn (Chonnam National University Hwasun Hospital, Korea)

ES03-1 Sezary syndrome and mycosis fungoides
Hyewon Lee (National Cancer Center, Korea)

ES03-2 Systemic mastocytosis
Hyun Jung Lee (Kyung Hee University College of Medicine, Korea)

ES03-3 Plasmacytoid dendritic cell neoplasm
Yoo Jin Lee (University of Ulsan College of Medicine, Korea)

DAILY PROGRAM Thursday, March 30

17:50-18:10 Break

18:10-19:30 **Welcome Reception** VISTA Hall Lobby

DAILY PROGRAM Friday, March 31

09:00-10:15 **[JS02] ASH-KSH Joint Symposium - T Cell Lymphoma** Room 1

Chairs Seongsoo Jang (University of Ulsan College of Medicine, Korea)
Robert Brodsky (John Hopkins University, USA)

JS02-1 NK cells: next generation cell therapies for cancer
Katy Rezvani (The University of Texas MD Anderson Cancer Center, USA)

JS02-2 Treatment of extranodal NK/T-cell lymphoma: Korean Lymphoma Working Party experience
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

JS02-3 CAR-T for the treatment of T cell malignancies
John DiPersio (Washington University School of Medicine, USA)

JS02-4 Treatment of peripheral T-cell lymphoma: Korean Lymphoma Working Party experience
Deok-Hwan Yang (Chonnam National University Medical School, Korea)

09:00-10:15 **[SS07] What is the direction of the new CAR-T therapy?** Room 2

Chairs Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea)
Je-Jung Lee (Chonnam National University Medical School, Korea)

SS07-1 Engineering next-generation T cells for cancer immunotherapy
Yvonne Chen (University of California, USA)

SS07-2 Development of CAR-T therapy for acute lymphoblastic leukemia
Hyoung Jin Kang (Seoul National University College of Medicine, Korea)

SS07-3 Updates on the latest developments in CAR-T therapies
Hiroshi Fujiwara (Mie University, Japan)

DAILY PROGRAM Friday, March 31

09:00-10:15 **[SS08] Comprehensive approaches to understand hemophilia** Room 3

Chairs Eun Jin Choi (Daegu Catholic University Hospital, Korea)
Ki Young Yoo (Korea Hemophilia Foundation, Korea)

SS08-1 Genotyping of hemophilia, why we need it and how we do?
Jill Johnsen (University of Washington, USA)

SS08-2 Value of national cohort registry data of hemophilia
Jung Woo Han (Yonsei University College of Medicine, Korea)

SS08-3 Essentials of laboratory issues in Emicizumab
Sang Hyuk Park (Ulsan University Hospital, Korea)

09:00-10:15 **[ES04] Back to the basic: transfusion support** Room 4

Chairs Jong Ho Won (Soonchunhyang University College of Medicine, Korea)
Jihyang Lim (College of Medicine, The Catholic University of Korea, Korea)

ES04-1 Transfusion support for HSCT
Dong Wook Jekarl (College of Medicine, The Catholic University of Korea, Korea)

ES04-2 Evidence based transfusion threshold
Dae-Hyun Ko (University of Ulsan College of Medicine, Korea)

ES04-3 Current status of manufactured blood cells
Eun Jung Baek (Hanyang University College of Medicine, Korea)

10:15-10:30 Break

10:30-11:15 **[PL02] Plenary Lecture 02** Room 1+2

Chair Chul-Ju Yoo (Yonsei University College of Medicine, Korea)

The role of the intestinal microbiome in cancer immunotherapy
Marcel van den Brink (Memorial Sloan Kettering Cancer Center, USA)

DAILY PROGRAM Friday, March 31

11:15-12:00 **Poster Viewing** Walker Hall

12:00-12:15 Break

12:15-13:05 **[SY04] Kyowa Kirin** Room 1

Chair Jong Wook Lee (College of Medicine, The Catholic University of Korea, Korea)

Recent advances in the pathogenesis and treatment of aplastic anemia
Kohei Hosokawa (Kanazawa University, Japan)

12:15-13:05 **[SY05] Handok** Room 2

Chair Je-Hwan Lee (University of Ulsan College of Medicine, Korea)

Value of intensive therapy in high-risk AML
Martin Bornhaeuser (University Hospital Carl Gustav Carus Dresden, Germany)

12:15-13:05 **[SY06] Janssen** Room 3

Chair Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)

When and whom to start treatment of CLL patients and how to optimally manage CLL patients with Imbruvica
Paolo Ghia (IRCCS Ospedale San Raffaele, Italy)

13:05-13:20 Break

13:20-14:50 **[OP04] Acute leukemia and Quality of life** Room 1

Chairs Inho Kim (Seoul National University Hospital, Korea)
Joon-ho Moon (Kyungpook National University School of Medicine, Korea)

DAILY PROGRAM Friday, March 31

OP04-1 A study on heterogeneity and early response to chemotherapy in children with ETV6-RUNX1 positive acute lymphoblastic leukemia by RNA-seq expression profile
Xueling Zheng (National Center for Children's Health, China)

OP04-2 Quality of sample is important for measurable residual disease with multiparameter flow cytometry in pediatric B acute lymphoblastic leukemia in direct comparison to next generation sequencing
Sang Mee Hwang (Seoul National University Bundang Hospital, Korea)

OP04-3 Evaluation of FTO polymorphisms in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia
Minu Singh (Postgraduate Institute of Medical Education and Research, India)

OP04-4 Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia; A multicenter, non-selected, retrospective cohort study
Suhyeon Kim (Jeonbuk National University Medical School, Korea)

OP04-5 Methods for analyzes and monitor of physiological data and quality of life in relation to chronic myeloid leukemia patients via wearable technology in Jaipur City, India
Vikas Sharma (S N Medical College and Hospital, India)

13:20-14:50 **[OP05] Bone marrow failure syndrome and myeloproliferative neoplasm** Room 2

Chairs Sukjoong Oh (Hanyang University Seoul Hospital, Korea)
Min Kyoung Kim (Yeungnam Univeristy Medical Center, Korea)

OP05-1 Clinical and genetic characteristics of myelodysplastic syndrome in young age
Eun-Ji Choi (University of Ulsan College of Medicine, Korea)

OP05-2 Reclassification of myelodysplastic neoplasm according to the 5th edition of the World Health Organization classification
Byunggyu Bae (College of Medicine, The Catholic University of Korea, Korea)

OP05-3 Response to immunosuppressive therapy in aplastic anemia patients - A single centre prospective study of 158 patients from a tertiary care centre in Southern India
Deepak Amalnath (Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India)

DAILY PROGRAM Friday, March 31

OP05-4 Mutational pattern of T-cell large granular lymphocyte leukemia (T-LGL): Low mutational burden of STAT3 in T-LGL combined with pure red cell aplasia
Sooyong Park (Seoul National University College of Medicine, Korea)

OP05-5 Abdominal aortic calcification in patients newly diagnosed with Philadelphia-negative myeloproliferative neoplasm
Myung-Won Lee (Chungnam National University College of Medicine, Korea)

OP05-6 A single-arm, open-label, multicenter study to assess molecular response of P1101 therapy in patients with polycythemia vera and elevated hematocrit
Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)

13:20-14:50 **[OP06] Multiple myeloma** Room 3

Chairs Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)
Won-Sik Lee (Inje University Busan Paik Hospital, Korea)

OP06-1 Outcome of multiple myeloma patients with Hepatitis B surface antigen: Korean multiple myeloma working 2103 study
Jun Ho Yi (Chung-Ang University College of Medicine, Korea)

OP06-2 Genetic alterations in multiple myeloma with extramedullary disease
Dajung Kim (Kosin University College of Medicine, Korea)

OP06-3 Epigenetic alteration in key genes and drug resistance in multiple myeloma
Seungbin Han (University Hospital of Wuerzburg, Germany)

OP06-4 Impaired death receptor signalling mediates cross-resistance to immunotherapy in MM
Umair Munawar (University Hospital Wuerzburg, Germany)

OP06-5 Antibody targeting of soluble MHC-class-I-related molecule augments natural killer cell function by restoring NKG2D in multiple myeloma
Hyunsoo Cho (Yonsei University College of Medicine, Korea)

OP06-6 Monocytic myeloid-derived suppressor cells expand but lose suppressive activity following stem cell mobilization with G-CSF in multiple myeloma patients
Egor Batorov (Research Institute of Fundamental and Clinical Immunology, Russia)

DAILY PROGRAM Friday, March 31

13:20-14:50 **[OP07] Anemia, bleeding and platelet** Room 4

Chairs Seong Kyu Park (Soonchunhyang University Bucheon Hospital, Korea)
Jaewoo Song (Yonsei University College of Medicine, Korea)

OP07-1 GC1126A, a novel ADAMTS13 mutein that evades autoantibody as a superior therapy for acquired thrombotic thrombocytopenic purpura (aTTP)
Hyun-Ja Nam (GC Biopharma, Korea)

OP07-2 Obesity is associated with poor response to corticosteroid-based therapy in chinese primary immune thrombocytopenia (ITP) patients
Gege Feng (Qilu Hospital of Shandong University, China)

OP07-3 Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia
Xinyi Zuo (Shandong University, China)

OP07-4 A Phase 1 study of the safety, tolerability, pharmacokinetics and pharmacodynamics of MG1113 in healthy subjects and hemophilia patients
Jung Woo Han (Yonsei Cancer Center, Yonsei University Health System, Korea)

OP07-5 Evaluation of safety and efficacy of hbs-sailin®: A potent ingenious anti-sickling agent that reduces pain and improves the quality of life in sickle cell patients
Shruti Bhatt (University of Delhi South Campus, India)

OP07-6 Favorable outcomes of hematopoietic stem cell transplantation after fludarabine-based, radiation-free conditioning in children with inherited bone marrow failure syndrome
Suejung Jo (College of Medicine, The Catholic University of Korea, Korea)

14:50-15:05 Break

15:05-16:20 **[JS03] EHA-KSH Joint Symposium - Myelodysplastic Syndrome** Room 1

Chairs June-Won Cheong (Yonsei University College of Medicine, Korea)
Lionel Adès (Hospital Saint Louis and Paris University, France)

DAILY PROGRAM Friday, March 31

JS03-1 Novel approaches in MDS
Uwe Platzbecker (Leipzig University Hospital, Germany)

JS03-2 Treatment of MDS: Korean AML/MDS working party experience
June-Won Cheong (Yonsei University College of Medicine, Korea)

JS03-3 Standard management of MDS
Lionel Adès (Hospital Saint Louis and Paris University, France)

JS03-4 Genetic alterations in myelodysplastic neoplasms
Yoo-Jin Kim (College of Medicine, The Catholic University of Korea, Korea)

15:05-16:20 **[SS09] Which immune therapy is our future weapon against AML?** Room 2

Chairs Hyeoung-Joon Kim (Chonnam National University Medical School, Korea)
Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea)

SS09-1 Immune checkpoint inhibition for AML ; CD47 blockade and beyond
Naval Daver (MD Anderson Cancer Center, USA)

SS09-2 Determining the barriers to successful CAR T cell therapy for AML
Miriam Y Kim (University of Washington, USA)

SS09-3 Adoptive T cell transfer of three universal tumor associated antigens-specific T cells for the treatment of AML
Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)

15:05-16:20 **[SS10] Next-generation molecular genomic and cytogenomic technology in hematology** Room 3

Chairs Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)
Yoon Hwan Chang (Seoul National University Hospital, Korea)

SS10-1 A transcriptomic approach to clinical diagnosis, prognosis and therapy selection in AML
Aly Karsan (University of British Columbia, Canada)

DAILY PROGRAM Friday, March 31

SS10-2 Whole genome sequencing of fluorescence in situ hybridized cells in hematologic malignancies using SLACS
Sunghoon Kwon (Seoul National University, Korea)

SS10-3 Next generation cytogenetics – optical mapping for comprehensive structural variant detection in hematological malignancies and beyond
Alexander Hoischen (Radboud University Medical Center, The Netherlands)

15:05-16:20 **[ES05] Practical issue in CAR-T** Room 4

Chairs Jae-Yong Kwak (Jeonbuk National University Hospital, Korea)
Hyoung Jin Kang (Seoul National University College of Medicine, Korea)

ES05-1 Setting up the facility for CAR T cell therapy
Ja Min Byun (Seoul National University College of Medicine, Korea)

ES05-2 Technical aspect of manufacturing CAR T cell product
Jong-Seo Lee (AbClon Inc., Korea)

ES05-3 Managing adverse events of CAR T cell therapy
Jae Won Yoo (College of Medicine, The Catholic University of Korea, Korea)

16:20-16:35 Break

16:35-17:50 **[JS04] International Collaborative Session - Aplastic Anemia** Room 2

Chairs Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
Lalita Norasetthada (Chiang Mai University, Thailand)

JS04-1 Overview of AA diagnosis and treatment in NIHBT, Vietnam
Nguyen Thi Thao (National Institute of Hematology and Blood Transfusion, Vietnam)

JS04-2 The incidence and real-world outcome of aplastic anemia in Thailand
Lalita Norasetthada (Chiang Mai University, Thailand)

JS04-3 Role of TPO receptor agonists in aplastic anemia treatment
Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

DAILY PROGRAM Friday, March 31

16:35-17:50 **[SS11] Liquid biopsy application in hematology** Room 3

Chairs Myung Geun Shin (Chonnam National University Medical School, Korea)
Seung-Tae Lee (Yonsei University College of Medicine, Korea)

SS11-1 Cell-free DNA profiling for monitoring of complications of hematopoietic cell transplantation
Iwijn De Vlaminck (Cornell University, USA)

SS11-2 Towards non-invasive monitoring of disease and microbe invasion in patients with hematologic malignancies
Charles Gawad (Stanford University, USA)

SS11-3 Clinical applications of circulating tumor DNA analysis in lymphoma
Seung-Tae Lee (Yonsei University College of Medicine, Korea)

16:35-17:50 **[SS12] Up-to-date diagnostic and treatment strategies of adult ALL patients** Room 4

Chairs Ho-Jin Shin (Pusan National University Hospital, Korea)
Seok Lee (College of Medicine, The Catholic University of Korea, Korea)

SS12-1 Are we moving towards a chemo- and transplant-free management of Ph-positive adult ALL?
Robin Foa (Sapienza University of Rome, Italy)

SS12-2 Development of more-effective CAR T-cell therapy for ALL
Saar I Gill (University of Pennsylvania, USA)

SS12-3 Overcoming high-risk features in adult ALL patients
Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea)

17:50-18:10 Break

DAILY PROGRAM Friday, March 31

18:10-18:40	**Cocktail Reception**	VISTA 3
18:40-20:00	**Gala Dinner**	VISTA 1+2

DAILY PROGRAM Saturday April 1

07:30-08:30 **Business Meeting** Room 4

08:30-09:00 **Working Party Report** Room 1

09:00-10:15 **[JS05] Asian Hematology Session II - Red Blood Cell Disorder** Room 1

Chairs Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)
Hyoung Soo Choi (Seoul National University College of Medicine, Korea)

JS05-1 Overview of thalassaemia and hemoglobinopathies in Bangladesh
Mahmood A. Chowdhury (Chattogram Maa-O-Shishu Hospital Medical College, Bangladesh)

JS05-2 Current situation of thalassemia care in Cambodia
Chean Sophâl (National Pediatric Hospital, Cambodia)

JS05-3 Epidemiology and diagnosis of hemolytic anemia in Korea
Heewon Chueh (Dong-A University College of Medicine, Korea)

09:00-10:15 **[SS13] Current knowledge of human hematopoietic stem cell** Room 2

Chairs Deog-Yeon Jo (Chungnam National University College of Medicine, Korea)
Byung-Soo Kim (Korea University College of Medicine, Korea)

SS13-1 Single cell HSPC map
William J. Greenleaf (Stanford University, USA)

SS13-2 Humanized mouse and non-human primate: Animal models for hematopoietic stem cell research
Kyung-Rok Yu (Seoul National University, Korea)

SS13-3 What we know about HSC homing?
Xinxin Huang (Fudan University, China)

DAILY PROGRAM Saturday April 1

09:00-10:15 **[SS14] What's new in chronic lymphocytic leukemia?** Room 3

Chairs Young Rok Do (Keimyung University School of Medicine, Korea)
Deok-Hwan Yang (Chonnam National University Medical School, Korea)

SS14-1 Translating scientific advances in CLL
Richard Rosenquist (Karolinska Institute, Sweden)

SS14-2 Patient selection for time limited versus continued therapy
Jennifer R. Brown (Dana-Farber Cancer Institute, USA)

SS14-3 MRD monitoring in CLL Patients
Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea)

09:00-10:15 **[ES06] Novel therapeutics for myeloproliferative neoplasms** Room 4

Chairs Sung-Yong Kim (Konkuk University School of Medicine, Korea)
Chul Won Choi (Korea University Guro Hospital, Korea)

ES06-1 Prognostication in MPNs (including mutation abnormalities)
Junshik Hong (Seoul National University Hospital, Korea)

ES06-2 Novel therapeutics for MF (including cyotpenic myelofibrosis)
Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)

ES06-3 Novel therapeutics for ET/PV
Seug Yun Yoon (Soonchunhyang University Seoul Hospital, Korea)

10:30-11:15 **[PL03] Plenary Lecture 03** Room 1+2

Chair Kyung Ha Ryu (Ewha Womans University, Korea)

Recent advance in the hematopoietic stem cell research
Toshio Suda (National University of Singapore, Singapore)

11:15-11:30 Break

11:30-12:00 **Award Ceremony & Closing** Room 1+2

ICKSH 2023

2023 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE
& KSH 65TH ANNIVERSARY

POSTER LIST

POSTER LIST

PP01-1 **Clinical Significance of bZIP in-frame CEBPA-mutated normal karyotype acute myeloid leukemia**

Seo-Yeon Ahn[1], TaeHyung Kim[2,3], Mihee Kim[1], Ga-Young Song[1], Sung-Hoon Jung[1], Deok-Hwan Yang[1], Je-Jung Lee[1], Mi Yeon Kim[4], Chul Won Jung[5], Jun-Ho Jang[5], Hee Je Kim[6], Joon Ho Moon[7], Sang Kyun Sohn[7], Jong-Ho Won[8], Sung-Hyun Kim[9], Hyeoung-Joon Kim[1,4], Jae-Sook Ahn[1,4*] and Dennis Dong Hwan Kim[10]

[1]Hematology-Oncology, Chonnam National University Hwasun Hospital, Korea
[2]The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Canada
[3]Computer Science, University of Toronto, Canada
[4]Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Korea
[5]Hematology-Oncology, Samsung Medical Center, Korea
[6]Hematology, Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea
[7]Hematology-Oncology, Kyungpook National University Hospital, Korea
[8]Hematology-Oncology, Soon Chun Hyang University Hospital, Korea
[9]Hematology-Oncology, Dong-A University College of Medicine, Korea
[10]Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Canada

PP01-2 **Candidate drug screening for TP53-mutated AML**

Daehyeon Gwak[1,2], Dong-Yeop Shin[1,2,3*], Dongchan Kim[1,2], Ja Min Byun[1,2,3], Youngil Koh[1,2,3], Junshik Hong[1,2,3] and Sung-Soo Yoon[1,2,3]

[1]Cancer Research Institute, Seoul National University College of Medicine, Korea
[2]Center for Medical Innovation of Biomedical Research Institute, Seoul National University Hospital, Korea
[3]Department of Internal Medicine, Seoul National University College of Medicine, Korea

PP01-3 **Prognostic relevance of MN1 expression in cytogenetically normal adult AML Patients**

Anita Chopra[1*], Aparna Ningombam[1], Deepak Verma[1], Rajive Kumar[1], Jay Singh[1], Shadab Ali[1], Avanish Panday[1], Inder Sigh[4], Sameer Bakhshi[2], Atul Sharma[2], Deepam Pushpam[2], Jayanth Palanichamy[3], Pranay Tanwar[1] and Amar Ranjan Singh[1]

[1]Laboratory Oncology, Professor, All India Institute Of Medical Science, India
[2]Medical Oncology, Professor, All India Institute Of Medical Science, India
[3]Biochemistry, Additional professor, All India Institute Of Medical Science, India
[4]Neurology, Scientist, All India Institute Of Medical Science, India

PP01-4 **Antileukemic activity of 1,3,5-Triazine (5-TC) against human leukemic cell via inhibition of EGFR-TK**

Udaya Pratap Singh[1*] and Hans Raj Bhat[2]

[1]Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, India
[2]Department of Pharmaceutical Sciences, Dibrugarh University, India

POSTER LIST

PP01-5 **Gilteritinib with chemotherapy in patients with newly diagnosed acute myeloid leukemia**

Masashi Sawa[1], Toshihiro Miyamoto[2], Hee-Je Kim[3], Yasushi Hiramatsu[4], June-Won Cheong[5*], Takayuki Ikezoe[6], Tomoki Naoe[7], Koichi Akashi[8], Satoshi Morita[9], Nahla Hasabou[10], Elizabeth Shima Rich[10], Masanori Kosako[11], Eiichiro Uemura[10], Wataru Terada[11], Takeshi Kadokura[11], Jason Hill[10] and Shuichi Miyawaki[12]

[1]*Department of Hematology and Oncology, Anjo Kosei Hospital, Japan*
[2]*Department of Hematology, Kanazawa University, Japan*
[3]*Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Korea*
[4]*Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Japan*
[5]*Department of Internal Medicine, Yonsei University College of Medicine, Korea*
[6]*Department of Hematology, Fukushima Medical University Hospital, Japan*
[7]*Department of Hematology and Oncology, National Hospital Organization Nagoya Medical Center, Japan*
[8]*Department of Medicine and Biosystemic Science, Kyushu University Hospital, Japan*
[9]*Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Japan*
[10]*Astellas Pharma US, Inc., USA*
[11]*Astellas Pharma Inc., Japan*
[12]*Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Japan*

PP01-10 **Mitochondrial Membrane potential as a metabolic related marker to enrich LSCs in AML**

Pingping Yang[1], Aibin Liang[1*], Wenjun Zhang[1] and Yufeng Shi[2]

[1]*Department of Haematology, Tongji Hospital, Tongji University School of Medicine, 1239 Siping Road, China*
[2]*Tongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University School of Medicine, China*

PP01-11 **Genetic, epigenetic, and clinical significance of Wilms' tumor 1 (WT1) gene in primary acute myeloid leukemia and its influence on prognosis**

Harsh Goel[1], Anita Chopra[1], Amar Ranjan[1], Jagdish Prasad Meena[2], Aditya Kumar Gupta[2], Ganesh Kumar Viswanathan[3], Sameer Bakhshi[4], Maroof Ahmad Khan[5] and Pranay Tanwar[1*]

[1]*Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India*
[2] *Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India*
[3]*Department of Hematology, All India Institute of Medical Sciences, New Delhi, India*
[4]*Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India*
[5]*Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India*

PP01-12 **Mutation of NPM1 and FLT3-ITD genes in acute myeloid leukemia and their association with clinico-pathological profile**

Smeeta Gajendra[1*], Nupur Das[1], Ritu Gupta[1], Deepshi Thakral[1], Sanjeev k Gupta[1], Sameer Bakshi[2], Ranjit K Sahoo [2] and Atul Sharma[2]

[1]*Laboratory Oncology, BRAIRCH, AIIMS, New Delhi, India*
[2]*Medical Oncology, BRAIRCH, AIIMS, New Delhi, India*

POSTER LIST

PP01-13 **Pursuing the clonal transition of minimal residual disease clones in patients with relapsed and refractory acute myeloid leukemia**

Dongchan Kim[1], Hyojin Song[2,3], Sung-Soo Yoon[1,4], Hongseok Yun[2,3] and Dong-Yeop Shin[1,4*]
[1]*Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea*
[2]*Center for Precision Medicine, Seoul National University Hospital, Seoul, Korea*
[3]*Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea*
[4]*Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea*

PP01-15 **Role of HOTAIRM1/miR-222 Axis in the pathogenesis of paediatric acute myeloid leukaemia**

Christine Wilson[1], Diwakar Sharma[1], Sachin Kumar [1], Jayanth K. Palanichamy[3], Anita Chopra [2], Sampa Ghose[1], Sameer Bakhshi[1] and Surender K. Sharawat[1*]
[1]*Medical Oncology, Dr. B R A IRCH, All India Institute of Medical Sciences, India*
[2]*Unit of Laboratory Oncology, Dr. B R A IRCH , All India Institute of Medical Sciences, India*
[3]*Biochemistry, All India Institute of Medical Sciences, India*

PP01-16 **Retrospective analysis of TP53 mutations in acute myeloid leukiemia: A single institute study**

Jae-Ryong Shim[1], Min-Sun Kwak[1] and Jin-Yeong Han[1*]
[1]*Department of Laboratory Medicine, Dong-A University College of Medicine, Korea*

PP01-17 **Role of LncRNA UCA1 long non-coding RNA in pediatric acute myeloid leukemia**

Surender K. Sharawat[1], Diwakar Sharma[1], Christine Wilson[1], Sampa Ghose[1], Sameer Bakhshi [1], Sachin Kumar[1] and Surender K. Sharawat[1*]
[1]*Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, India*

PP01-18 **Novel HOXA3-HOXA9 fusion genes in acute myeloid leukaemia: The bride or the bridesmaid?**

Angeli Ambayya[1,2*], Rozaimi Razali[3], Sarina Sulong[4], Jameela Sathar[2] and Rosline Hassan[1]
[1]*Department of Haematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 15159, Kelantan, Malaysia*
[2]*Clinical Haematology Referral Laboratory, Haematology Department, Hospital Ampang, Ministry of Health Malaysia, Ampang 68000, Selangor, Malaysia*
[3]*Department of Biomedical Sciences, Qatar University, Qatar*
[4]*Human Genome Centre, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 15159, Kelantan, Malaysia*

POSTER LIST

PP01-19 **Not only mutations matter: Deciphering the gene expression profiles of FLT3 and NPM1 in acute myeloid leukaemia-normal karyotype by transcriptome sequencing**

Angeli Ambayya[1,2*], Rozaimi Razali[1], Sarina Sulong[3], Jameela Sathar[2] and Rosline Hassan[1]
[1]*Department of Haematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 15159, Kelantan, Malaysia*
[2]*Clinical Haematology Referral Laboratory, Haematology Department, Hospital Ampang, Ministry of Health Malaysia, Ampang 68000, Selangor, Malaysia*
[3]*Human Genome Centre, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 15159, Kelantan, Malaysia*

PP01-20 **Reclassification of acute myeloid leukemia and higher-risk myelodysplastic syndrome based on the new International Consensus Classification**

Hye-Seong Ryu[1], Young-Uk Cho[1*], Daehyun Chu[1], Miyoung Kim[1], Seongsoo Jang[1], Chan-Jeoung Park[1], Eul-Ju Seo[1] and Sang-Hyun Hwang[1]
[1]*Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*

PP01-22 **Unveiling of some novel compounds to inhibit the overexpressed genes of acute myeloid leukemia for the new therapeutics discovery**

Khaleda Jahan Satu[1] and Mohammad Uzzal Hossain[2*]
[1]*Department of Chemistry, Mawlana Bhashani Science and Technology University, Bangladesh*
[2]*Bioinformatics Division, National Institute of Biotechnology, Bangladesh*

PP01-23 **A prospective study to evaluate the prognostic implications of MMP-2 gene in acute myeloid leukemia**

Harsh Goel[1], Anita Chopra[1], Amar Ranjan[1], Aditya Kumar Gupta[2], Jagdish Prasad Meena[2], Ganesh Kumar Viswanathan[3], Sameer Bakhshi[4], Maroof Ahmad Khan[5] and Pranay Tanwar[1*]
[1]*Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India*
[2] *Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India*
[3]*Department of Hematology, All India Institute of Medical Sciences, New Delhi, India*
[4]*Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India*
[5]*Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India*

PP01-24 **Azacytidine venetoclax posaconazole combination in the treatment of acute myeloid leukemia in a resource limited setting: A single centre experience**

Nitin Gupta[1*], Deepika Gupta[1], Priyanka Moule[1], Chetan Agarwal[1], Vandana Arya[2] and Jyoti Kotwal[2]
[1]*Clinical Hematology, Sir Ganga Ram Hospital, New Delhi, India*
[2]*Hematopathology and molecular hematology, Sir Ganga Ram Hospital, New Delhi, India*

POSTER LIST

PP01-26 **Discovery of neoantigens using artificial intelligence (NEO-ARSTM) in AML: A pilot study**

Suyoung Choi[1,2,3], Joo-Young Kang[4], Hyun-Jin Yang[4], Jeong-Yeon Park[5], Il-Oh Jeong[5], Jong Hui Hong[5], Jongsun Jung[5], Thi Thuy Duong Pham[1,2,3], Bu-Yeon Heo[1,2,3], Jeong Suk Koh[6], Myung-Won Lee[6], Jung-Hyun Park[7], Yunsun Jang[7], Deog-Yeon Jo[6], Jaeyul Kwon[1,2,3,7,8] and Ik-Chan Song[1,3,6*]

[1]Department of Medical Science, College of Medicine, Chungnam National University, Korea
[2]Department of Infection Biology, College of Medicine, Chungnam National University, Korea
[3]Brain Korea 21 FOUR Project for Medical Science, Chungnam National University, Korea
[4]Genome Data Integration Centre, Syntekabio Inc., Seoul, Korea
[5]Medical Science Study Centre, Syntekabio Inc., Daejeon, Korea
[6]Department of Internal Medicine, College of Medicine, Chungnam National University, Korea
[7]Translational Immunology Institute, College of Medicine, Chungnam National University, Korea
[8]Department of Medical Education, College of Medicine, Chungnam National University, Korea

PP01-27 **Effects of venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia in clinical settings**

Young Seob Park[1], Min Kyoung Kim[1*], Sung Hwa Bae[2], Sang Kyun Sohn[3], Joon Ho Moon[3], Hee Jeong Cho[3], Juhyung Kim[3], Young Rok Do[4], Mi Hwa Heo[4] and Jung Min Lee[4]

[1]Department of Hematology and Oncology, Yeungnam University College of Medicine, Daegu, Korea
[2]Department of Hematology and Oncology, Daegu Catholic University Medical Center, Daegu, Korea
[3]Department of Hematology and Oncology, Kyungpook National University Hospital, Daegu, Korea
[4]Department of Hematology and Oncology, Keimyung University School of Medicine, Daegu, Korea

PP01-29 **The role of estrogen related receptor alpha (ERRα) as therapeutic target of acute myeloid leukemia**

Wonhyouong Seo[1], Ik-Chan Song [2], Kyung Tae Kim [1], Sang Min Jeon[1], Taylor Roh [1] and Eun-Kyeong Jo[1*]

[1]Department of Medical Science, Chungnam National University College of Medicine, Korea
[2]Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Korea

PP01-30 **Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia**

Junshik Hong[1*], Jun Liu[1], Suji Min[1] and Sung-Soo Yoon[1]

[1]Department of Internal Medicine, Seoul National University Hospital, Korea

POSTER LIST

PP01-31 **Differences of categories and their prognosis between the International Consensus Classification 2022 and the 5th World Health Organization classification in acute myeloid leukemia**

Jin Jung[1,2], Daehun Kwag[3], Hoon Seok Kim[1,2], Jong-Mi Lee[1,2], Ari Ahn[1,2], Byung-Sik Cho[3], Hee-Je Kim[3], Yonggoo Kim[1,2], and Myungshin Kim[1,2]

[1]Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
[2]Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
[3]Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP01-32 **Physical function in older adults with acute myeloid leukemia treated with hypomethylating agents with or without venetoclax**

Daehun Kwag[1,2], Su-yeon Bang[1,2], Jong Hyuk Lee[1,2], Gi-June Min[1,2], Sung-Soo Park[1,2], Silvia Park[1,2], Jae-Ho Yoon[1,2], Sung-Eun Lee[1,2], Ki-Seong Eom[1,2], Yoo-Jin Kim[1,2], Seok Lee[1,2], Hee-Je Kim[1,2], Chang-Ki Min[1,2], Seok-Goo Cho[1], Jong Wook Lee[1], and Byung-Sik Cho[1,2]

[1]Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
[2]Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP02-1 **Proerythroblasts as the main erythroid dysplasia in myelodysplastic syndrome**

Hyunjung Kim

Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP02-2 **Is MDS really treatable in Pakistan? Gaps and challenge- Single centre experience from Pakistan**

Nida Anwar[1*], Uzma Mahar[1], Aisha Arshad[1], Naveena Fatima[2], Sumaira Sharif[2] and Tahir Shamsi[1]

[1]Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan
[2]Research and Development, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan

PP02-3 **Significance of platelet count at diagnosis and its association with survival in MDS Patients; An experience from Pakistan**

Nida Anwar[1*], Naveena Fatima[2], Aisha Arshad[1], Anum Khalid[2] and Laraib Majeed[2]

[1]Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan
[2]Research and Development, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan

POSTER LIST

PP02-4 **Impact of transfusion burden in lower-risk MDS**

Jungmin Lee[1], Juhyung Kim[2], Hee Jeong Cho[2], Dong Won Baek[3], Ji Yeon Ham[4], Soon Hee Chang[5], Sang Kyun Sohn[2] and Joon Ho Moon[2*]

[1]Department of Hematology/Oncology, Keimyung University Dongsan Hospital, Korea
[2]Department of Hematology/Oncology, Kyungpook National University Hospital, Korea
[3]Department of Hematology/Oncology, Kyungpook National University Chilgok Hospital, Korea
[4]Department of Laboratory Medicine, Kyungpook National University Chilgok Hospital, Korea
[5]Department of Laboratory Medicine, Kyungpook National University Hospital, Korea

PP02-5 **A rare case of coexisting myelodysplastic syndrome and T-cell lymphoproliferative disorder**

Yuna Choi[1], Miyoung Kim[1*], Young-Uk Cho[1], Sang-Hyun Hwang[1], Seongsoo Jang[1], Eul-Ju Seo[1], Eun-Ji Choi[2], Han-Seung Park[2] and Chan-Jeoung Park[1]

[1]Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Korea
[2]Department of Haematology, Asan Medical Center, University of Ulsan College of Medicine, Korea

PP02-6 **Myelodysplastic syndrome occurrence in post-therapeutic systemic lupus erythematosus patients**

Adika Zhulhi Arjana[1] and Umi Solekhah Intansari[1*]

[1]Clinical Pathology and Laboratory Medicine, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Indonesia

PP02-7 **Next-generation sequencing as an essential test in addition to conventional cytogenetics for the diagnosis of hypoplastic myelodysplastic neoplasm**

Min-Kyung So[1], Sholhui Park[1], Dong Jin Park[1], Young Hoon Park[2], Yeung-Chul Mun[2] and Jung-won Huh[1*]

[1]Department of Laboratory Medicine, Ewha Womans University College of Medicine, Korea
[2]Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University College of Medicine, Korea

PP02-8 **SF3B1-mutated myeloid neoplasms: pathologic correlation focusing on myelodysplastic syndrome with mutated SF3B1**

Daehyun Chu[1], Young-Uk Cho[1*], Miyoung Kim[1], Sang-Hyun Hwang[1], Seongsoo Jang[1], Eul-Ju Seo[1] and Chan-Jeoung Park[1]

[1]Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

PP03-1 **The challenges in managing Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and young adults (AYA) treated with MASPORE**

Yang Liang Boo[1*], Christopher Chin Keong Liam[1], Yih Seong Wong[1], Azizan Sharif[1] and Soo Min Lim[1]

[1]Department of Hematology, Sultanah Aminah Hospital, Malaysia

POSTER LIST

PP03-6 **B-Lymphoblastic leukemia acquiring BCR::ABL1 rearrangement upon relapse: A Case Report**

Jinho Lee[1], Hongkyung Kim[1], Won Kee Ahn[2], Seungmin Hahn[2] and Saeam Shin[1*]
[1]Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
[2]Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea

PP03-14 **Machine learning-based detection of leukocyte counts in microscopic images of acute lymphoblastic leukemia**

Rifaldy Fajar[1], Nick Nieber[1] and Peter Val[1]
[1]Mathematical Medicine Laboratory, Karlstad University, Sweden

PP03-16 **Bilateral facial nerve palsy in t-cell acute lymphoblastic leukemia: A case report and review of the literature**

Jhicel Ibañez[1*] and Jeremiah Vallente[1]
[1]Department of Internal Medicine, Mariano Marcos Memorial Hospital and Medical Center, Philippines

PP03-18 **Usefulness of immunoglobulin gene rearrangement analysis using next-generation sequencing in adult and pediatric B-lymphoblastic leukemia**

Daehyun Chu[1], Miyoung Kim[1*], Young-Uk Cho[1], Sang-Hyun Hwang[1], Seongsoo Jang[1], Eul-Ju Seo[1], Chan-Jeoung Park[1], Han-Seung Park[2], Jung-Hee Lee[2], Hyery Kim[3] and Ho Joon Im[3]
[1]Department of Laboratory Medicine, Asan Medical Center, Korea
[2]Department of Hematology, Asan Medical Center, Korea
[3]Department of Pediatric Hematology & Oncology, Asan Medical Center, Korea

PP03-19 **Analysis of marrow infiltrating T cell at 3 months after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies**

Thi Thuy Duong Pham[1,2,3], Su-young Choi[1,2,3], Bu-Yeon Heo[1,2,3], Jeong Suk Koh[6], Myung-Won Lee[6], Jung-Hyun Park[4], Yunsun Jang[4], Deog-Yeon Jo[6], Jaeyul Kwon[1,2,5] and Ik-Chan Song[6*]
[1]Department of Medical Science, College of Medicine, Chungnam National University, Korea
[2]Department of Infection Biology, College of Medicine, Chungnam National University, Korea
[3]Brain Korea 21 FOUR Project for Medical Science, Chungnam National University, Korea
[4]Translational Immunology Institute, College of Medicine, Chungnam National University, Korea
[5]Department of Medical Education, College of Medicine, Chungnam National University, Korea
[6]Department of Internal Medicine, College of Medicine, Chungnam National University, Korea

POSTER LIST

PP03-20 **Poor prognosis of IKZF1 and CDKN2 gene deletions in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia**

Jae-Ho Yoon[1], Daehun Kwag[1], Jong-Hyuk Lee[1], Gi June Min[1], Sung-Soo Park[1], Silvia Park[1], Sung-Eun Lee[1], Byung-Sik Cho[1], Ki-Seong Eom[1], Yoo-Jin Kim[1], Hee-Je Kim[1], Chang-Ki Min[1], Seok-Goo Cho[1], Jong Wook Lee[1] and Seok Lee[1*]

[1]Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP03-21 **Real-world experiences of inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia**

Jae-Ho Yoon[1], Daehun Kwag[1], Gi June Min[1], Sung-Soo Park[1], Silvia Park[1], Sung-Eun Lee[1], Byung-Sik Cho[1], Ki-Seong Eom[1], Yoo-Jin Kim[1], Hee-Je Kim[1], Chang-Ki Min[1], Seok-Goo Cho[1], Jong Wook Lee[1] and Seok Lee[1*]

[1]Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP03-22 **A fatal pneumatosis intestinalis after ponatinib treatment on a relapsed Philadephia-positive acute lymphoblastic leukemia patient: A case report**

Jong Hyuk Lee[1], Seok Lee[1*], Jae-Ho Yoon[1], Daehun Kwag[1], Gi-June Min[1], Sung-Soo Park[1], Silvia Park[1], Sung-Eun Lee[1], Ki-Seong Eom[1], Byung-Sik Cho[1], Yoo-Jin Kim[1], Chang-Ki Min[1], Seok-Goo Cho[1], Jong Wook Lee[1] and Hee-Je Kim[1]

[1]Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea

PP04-2 **A rare case of three way Philadelphia variant (9;11;22)(p11.2;q34;q11.2) & del(12) in chronic myeloid leukemia: A case report**

Noorulain Fareed[1], Noor Muhammad Somroo[1], Ghulam Fatima[1] and Saba Aman[1]

[1]Hematology, Dow university of health sciences/chk central lab civil hospital karachi, Pakistan

PP04-3 **Retrospective study of subsequent line nilotinib in chronic myeloid leukemia patients**

Ram Kumar Mummoorthy[1*], Jayachandran Perumal Kalaiyarasi[1], Nikita Mehra[1], Parathan Karunakaran[1], Venkatraman Radhakrishnan[1] and Krishnarathinam Kannan[1]

[1]Medical Oncology, Cancer Institute (WIA), Chennai, India

PP04-4 **Targeting CXCR2 overcome intolerance to ponatinib via AKT/mTOR and MYC signaling in chronic myeloid leukemia cells**

Ji-Hea Kim[1,2], Ji-Hyeon Hong[1,2] and Byung-Soo Kim[3*]

[1]Korea stem cell research institute, Korea University College of Medicine, Korea
[2]Biomedial Science, Korea University College of Medicine, Korea
[3]Internal Medicine, Anam Hospital Korea University Medical Center, Korea

POSTER LIST

PP04-5 **A case of chronic myeloid leukemia with novel X-linked four-way Philadelphia chromosome and molecular unresponsiveness with clonal evolution**
Sooeung Park[1], Hye Jin Kang[2], Ae-Chin Oh[1], Jin Kyung Lee[1], Young Jun Hong[1] and Heyjin Kim[1*]
[1]*Department of Laboratory Medicine, Korea Cancer Center Hospital, Korea*
[2]*Department of Internal Medicine, Korea Cancer Center Hospital, Korea*

PP04-6 **Investigation of the regulatory landscape of transcription modulators in chronic myeloid leukemia for the new biomarker discovery**
Mohammad Uzzal Hossain
Bioinformatics Division, National Institute of Biotechnology, Bangladesh

PP05-1 **Outcome of hematopoietic stem cell transplantation for pediatric lymphoma : A retrospective analysis of a single-center**
Hongbo He
Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing Children's Hospital, China

PP05-2 **Loss of ccar2 is associated with a better outcome in burkitt lymphoma cells**
Pingping Yang[1], Wenjun Zhang[1], Aibin Liang[1*], Lixin Lv[1] and Jinyuan Lu[1]
[1]*Department of Haematology, Tongji Hospital, Tongji University School of Medicine, 1239 Siping Road, China*

PP05-3 **The iminent role of alk inhibitors in relapsed and refractory ALK positive anaplastic large cell lymphoma**
Jayachandran Perumal Kalaiyarasi[1*], Indhuja Muthiah Vaikundaraja[1], Sivasree Kesana[1], Nikita Mehra[1], Parathan Karunakaran[1], Arun Kumar Rajan[1] and Venkatraman Radhakrishnan[1]
[1]*Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, India*

PP05-4 **Reduced dose rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy for diffuse large b-cell lymphoma (DLBCL); A practical approach for the elderly and frail**
Christopher Chin Keong Liam[1*], Yang Liang Boo[1], Yih Seong Wong[1], Azizan Sharif[1] and Soo Min Lim[1]
[1]*Hematology Unit, Department of Medicine, Hospital Sultanah Aminah, Johor Bahru, Malaysia*

PP05-5 **Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: A systematic review of 63 patients reported in the literature**
Wenxin Ou
Beijing Children's Hospital, Capital Medical University, China

PP05-6 **Indolent extranodal NK/T-cell lymphoma of the gastrointestinal tract mimicking indolent T-cell lymphoproliferative disorder of the gastrointestinal tract**
Shih-Sung Chuang
Pathology, Chi-Mei Medical Center, Tainan, Taiwan

POSTER LIST

PP05-7 **Transcriptomic profiling of double-hit lymphoma patients identifies aberrant ALOX5 captures vulnerability to ferroptosis**

Syahru Agung Setiawan[1,3,5], Chia-Hwa Lee[2], Mardiah Suci Hardianti[3], YunRu Liu[4], Chi-Tai Yeh[5] and Tsu-Yi Chao[6*]

[1]International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taiwan
[2]School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taiwan
[3]Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Indonesia
[4]Joint Biobank Office of Human Research, Taipei Medical University, Taiwan
[5]Department of Medical Research & Education, , Taipei Medical University-Shuang Ho Hospital, Taiwan
[6]Department of Hematology & Oncology, Taipei Medical University-Shuang Ho Hospital, Taiwan

PP05-8 **Long-term clinical outcomes of follicular lymphoma: A single-center experience of 275 patients in Catholic Hematology Hospital**

Gi June Min[1], Seok-Goo Cho[1*], Su-Yeon Bang[1], Young-Woo Jeon[2], Tong Yoon Kim[2], Byung-Su Kim[3], Joonyeop Lee[3], Daehun Kwag[1], Jong Hyuk Lee[1], Sung-Soo Park[1], Silvia Park[1], Jae-Ho Yoon[1], Sung-Eun Lee[1], Byung-Sik Cho[1], Ki-Seong Eom[1], Yoo-Jin Kim[1], Seok Lee[1], Hee-Je Kim[1], Chang-Ki Min[1] and Jong Wook Lee[1]

[1]Department of Hematology, Seoul St. Mary's Hematology Hospital, Korea
[2]Department of Hematology, Yeouido St. Mary's Hematology Hospital, Korea
[3]Department of Hematology, Eunpyeong St. Mary's Hematology Hospital, Korea

PP05-9 **A case report: primary pulmonary malt lymphoma in Ho Chi Minh City**

Duong Thao Quyen Nguyen[1], Nguyen Phuong Dung Co[2*] and Quoc Thanh Nguyen[3]

[1]Hematology, The Blood Transfusion Hematology Hospital, Viet Nam
[2]Hematology, Pham Ngoc Thach University of Medicine, Viet Nam
[3]Hematology, Ho Chi Minh City Medicine and Pharmacy University, Viet Nam

PP05-10 **Prognostic significances of molecular assay in primary central nervous system lymphoma**

Yu Ri Kim

Division of Hematology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Korea

PP05-11 **PET-adapted approach in advanced Hodgkin lymphoma: A single centre experience**

Yang Liang Boo[1*], Christopher Chin Keong liam[1], Wei Quan Low[1], Yih Seong Wong[1], Azizan Sharif[1] and Soo Min Lim[1]

[1]Department of Hematology, Sultanah Aminah Hospital, Malaysia

POSTER LIST

PP05-13 **Subcutaneous epcoritamab + rituximab and lenalidomide (R2) vs R2 for relapsed/refractory follicular lymphoma: EPCORE FL-1**

Sang-Hee Kim[10], Lorenzo Falchi[1*], Franck Morschhauser[2], John Gribben[3], Huiqiang Huang[4], Minh Dinh[5], Rebekah Conlon[5], Xiaorong Chen[6], Brian Elliott[7] and John F. Seymour[8,9]

[1]*Lymphoma Service, Memorial Sloan Kettering Cancer Center, USA*
[2]*Hematology, Hôpital Claude Huriez, France*
[3]*Barts Cancer Institute, Queen Mary University of London, UK*
[4]*Medical Oncology, Sun Yat-sen University, China*
[5]*Clinical Development Oncology, AbbVie, USA*
[6]*Statistics, AbbVie, USA*
[7]*Medical (Hematology), Genmab, USA*
[8]*Clinical Research, Peter MacCallum Cancer Centre, Australia*
[9]*Integrated Haematology, The Royal Melbourne Hospital, Australia*
[10]*Medical Affair, Abbvie, Korea*

PP05-14 **Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1–3a: phase 2 Study (ELM-2) prespecified analysis results**

Seok-Goo Cho[3], Tae Min Kim[1*], Michal Taszner[2], Silvana Novelli[4], Steven Le Gouill[5], Michelle Poon[6], Jose C. Villasboas[7], Rebecca Champion[8], Emmanuel Bachy[9], Stephanie Guidez[10], Aranzazu Alonso[11], Deepa Jagadeesh[12], Michele Merli[13], David Tucker[14], Jingxian Cai[15], Carolina Leite de Oliveira[15], Min Zhu[15], Aafia Chaudhry[15], Hesham Mohamed[15], Srikanth Ambati[15] and Stefano Luminari[16]

[1]*Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea*
[2]*Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland*
[3]*Department of Hematology, The Catholic University of Korea, Seoul St. Mary's Hospital Hematology, Seoul, Korea*
[4]*Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*
[5]*Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France*
[6]*Department of Haematology-Oncology, Hematology Oncology National University Hospital, Singapore*
[7]*Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA*
[8]*Heme Malignancies and Cellular Therapy, Norton Cancer Institute, Louisville, KY, USA*
[9]*Hematology Department, Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France*
[10]*Service d'Hématologie et Thérapie cellulaire, Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France*
[11]*Hematology and Hemotherapy, Hospital Universitario Quiron Salud Madrid, Madrid, Spain*
[12]*Department of Hematology and Medical Oncology, Cleveland Clinic Main Campus, Cleveland, OH, USA*
[13]*Department of Hematology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy*
[14]*Department of Haematology, Royal Cornwall Hospital, Cornwall, UK*
[15]*Hematology/Oncology department, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA*
[16]*Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy*

POSTER LIST

PP05-15 **Patterns of nodal and extranodal involvement in diffuse large B-cell lymphoma**

Moonho Kim[1] and Yongchel Ahn[1*]
[1]*Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Korea*

PP05-16 **MYD88 strongly associated with extranodal involvement in diffuse large B-cell lymphoma**

Jinhang Kim[1], Uiju Cho[2], Nanyoung Yun[1] and Jeong-A Kim[1*]
[1]*Hematology, St. Vincent Hospital, The Catholic University of Korea, Korea*
[2]*Pathology, St. Vincent Hospital, The Catholic University of Korea, Korea*

PP05-17 **A Novel CD19-directed car t cell therapy (AT101) targeting a pristine membrane-proximal epitope under phase I clinical trial**

Ki Hyun Kim[1], Soohwan Kim[1], Sung-Min Kim[1], Jong-Ho Lee[1], Hyun-Jong Lee[1], Ji-Ho Park[1], LeiGuang Cui[1], Min Yoon[1], Ki-Hyun Kim[2], Soohyun Kim[2], In-Sik Hwang[1], Youngha Lee[1], Jong-Hoon Kim[1], Hyungwoo Cho[3], Jong-Seo Lee[1], Dok Hyun Yoon[3] and Junho Chung[2*]
[1]*R&D Center, AbClon Inc., Korea*
[2]*Cancer Research Institute, Seoul National University College of Medicine, Korea*
[3]*Asan Medical Center, University of Ulsan College of Medicine, Korea*

PP05-18 **Impact of time-variant variable as cycle threshold with COVID19 infection in patients treated with rituximab and bendamustine for mature B cell lymphomas**

Tong Yoon Kim[1], Gi June Min[2], Sung Soo Park[2], Jung Yeon Lee[2], Byung-Su Kim[3], Chang-Ki Min[2], Seok-Goo Cho[2] and Young-Woo Jeon[1*]
[1]*Department of Hematology, Yeoido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea*
[2]*Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea*
[3]*Department of Hematology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea*

PP05-19 **Trial in progress: A phase 2 basket trial of nanatinostat in combination with valganciclovir in patients with EBV-Positive (EBV+) relapsed/refractory lymphomas (NAVAL-1)**

Young-Rok Do[1*], Won Sik Lee[2], Jae Hoon Lee[3], Dong Won Baek[4], Seok-Goo Cho[5], Donald Strickland[6] and Lisa Rojkjaer[6]
[1]*Division of Hemato-Oncology, Keimyung University Dongsan Hospital, Korea*
[2]*Department of Internal Medicine, Hemato-Oncology, Inje University Haeundae Paik Hospital, Korea*
[3]*Department of Hematology Oncology, Gachon University Gil Medical Center, Gachon University College of Medicine, Korea*
[4]*Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Korea*
[5]*Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea*
[6]*Medical , Viracta Thearpeutics Inc., USA*

POSTER LIST

PP05-20 **The outcome of hematopoietic stem cell transplantation for pediatric patients with lymphoma: A single-center study**

Wonkee Ahn[1], Seungmin Hahn[1], Jung Woo Han[1] and Chuhl Joo Lyu[1*]
[1]*Department of Pediatrics, Yonsei Cancer Center, Korea*

PP05-21 **A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: CISL1803 BRAVO study**

Seok Jin Kim[1*], Young Rok Do[2], Ho-Sup Lee[3], Won-Sik Lee[4], Jee Hyun Kong[5], Deok-Hwan Yang[6], Jae-Yong Kwak[7], Hyeon-Seok Eom[8], Joon Ho Moon[9], Jun Ho Yi[10], Jeong-Ok Lee[11] and Jae-Cheol Jo[12]
[1]*Medicine, Samsung Medical Center, Korea*
[2]*Medicine, Dongsan Medical Center, Korea*
[3]*Internal Medicine, Kosin University Gospel Hospital, Korea*
[4]*Internal Medicine, Inje University Busan Paik Hospital, Korea*
[5]*Internal Medicine, Wonju Severance Christian Hospital, Korea*
[6]*Internal Medicine, Chonnam National University Hwasun Hospital, Korea*
[7]*Internal Medicine, Chonbuk National University Medical School, Korea*
[8]*Hematology-Oncology Clinic, National Cancer Center, Korea*
[9]*Hematology/Oncology, Kyungpook National University Hospital, Korea*
[10]*Internal Medicine, Chung-Ang University Hospital, Korea*
[11]*Internal Medicine, Seoul National University Bundang Hospital, Korea*
[12]*Hematology and Oncology, Ulsan University Hospital, Korea*

PP05-22 **MicroRNA 340-5p-mediated PD-L1 expression in the etoposide-resistant NK/T-cell lymphoma**

Kyung Ju Ryu[1], Bon Park[1], Sang Eun Yoon[2], Won Seog Kim[1,2], Chaehwa Park[1] and Seok Jin Kim[1,2*]
[1]*Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Korea*
[2]*Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*

PP05-23 **Role of MiR-155-5p in ibrutinib-resistant diffuse large B cell lymphoma cells**

Bon Park[1], Myung Eun Choi[1], Kyung Ju Ryu[1], Jung Yong Hong[2], Won Seog Kim[1,2], Chaehwa Park[1] and Seok Jin Kim[1,2*]
[1]*Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Korea*
[2]*Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*

POSTER LIST

PP05-24 **Detection of tumor-derived mutations using liquid biopsy of plasma and cerebrospinal fluid in primary central nervous system lymphoma**

Yu Ri Kim

Division of Hematology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Korea

PP05-25 **Exploratory study on circulating tumor DNA characteristics in various lymphomas**

Hongkyung Kim[1], Hyunsoo Cho[2], Haerim Chung[2], Yu Ri Kim[2], Seung-Tae Lee[1], Jong Rak Choi[1], Saeam Shin[1*] and Jin Seok Kim[2]

[1]*Department of Laboratory Medicine, Yonsei University College of Medicine, Korea*
[2]*Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Korea*

PP05-26 **A comprehensive analysis of relapse pattern in patients with DLBCL after chemoimmunotherapy using national health insurance database of South Korea**

Hyun Jung Lee[1], Dong Wook Kim[3], Jae Joon Han[1] and Myung Hee Chang[2*]

[1]*Internal Medicine, Kyung Hee University Medical Center, Korea*
[2]*Internal Medicine, National Health Insurance Service Ilsan Hospital, Korea*
[3]*Information and Statistics, Gyeongsang National University, Korea*

PP05-27 **Whole genome sequencing reveals clinicogenetic characteristics of blastic plamacytoid dendritic cell neoplasms in South Korea: CISL1906 study**

Ji Hyun Lee[1], Sung-Yong Oh[1], Saeam Shin[1], Seung-Tae Lee[1], Namhee Kim[1], Min Kyung Pak[1], Sung-Soo Yoon[2], Youngil Koh[2], Ja Min Byun[2], Cheolwon Suh[2], Dok Hyun Yoon[2], Jae-Cheol Jo[2], Deok-Hwan Yang[3], Seo-Yeon Ahn[3], Hyeon Seok Eom[3], Hyewon Lee[3], Ji Yun Lee[4], Jong Ho Won[4], Ho-Young Yhim[5], Ho Sup Lee[6], Won Seog Kim[7] and Seok Jin Kim[7*]

[1]*Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Korea*
[2]*Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Korea*
[3]*Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Korea*
[4]*Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea*
[5]*Department of Internal Medicine, Keimyung University School of Medicine, Korea*
[6]*Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Korea*
[7]*Division of Hemato-oncology, Department of Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Korea*

POSTER LIST

PP06-1 **Cladribine combined with cytarabine regimen as a salvage therapy for paediatric refractory/relapsed langerhans cell histiocytosis: A single-armed, single-center study**
Ang Wei[1], Honghao Ma[1], Tianyou Wang[1] and Rui Zhang[1*]
[1]Hematology center, Beijing children's hospital, China

PP06-2 **Serum cytokine pattern in children with hemophagocytic lymphohistiocytosis**
Wenxin Ou
Beijing Children's Hospital, Capital Medical University, China

PP06-3 **A case of favorable outcome with pembrolizuamb for refractory histiocytic sarcoma**
Hyeon Gyu Yi
Department of Oncology and Hematology, Vinmec International Hospital, Viet Nam

PP07-3 **Immunological features and cytokine regulation in plasma cell neoplasms**
Zhanna Kozich[1], Natalya Klimkovich[2], Victor Martinkov[1] and Janna Pugacheva[1]
[1]Hematology Department, Republican Research Center for Radiation Medicine and Human Ecology, Belarus
[2]Hematology Department, Belarusian Medical Academy for Postgraduate Education, Belarus

PP07-4 **Prognostic value of serum free light chains measurements in newly diagnosed multiple myeloma patients at the Blood Transfusion Hematology Hospital**
Loc Thi Cao[1*] and Van Thanh Nguyen phan[2]
[1]Adult Hematology Department no.1, Blood Transfusion Hematology Hospital, Viet Nam
[2]Department of Biochemistry, Pham Ngoc Thach University of Medicine, Viet Nam

PP07-5 **Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide/dexamethasone-containing regimens (KMM170)**
Ga-Young Song[1], Sung-Hoon Jung[1], Joon Ho Moon[2], Dajung Kim[3], Min Kyoung Kim[4], Hyo Jung Kim[5], Yeung-Chul Mun[6], Won-Sik Lee[7], Young Rok Do[8], Jae Hoon Lee[9], Je-Jung Lee[1*] and Jin Seok Kim[10]
[1]Hematology-Oncology, Chonnam National University Hwasun Hospital, Korea
[2]Department of Hematology-Oncology, Kyungpook National University Hospital, Korea
[3]Department of Hematology, Kosin University Gospel Hospital, Korea
[4]Department of Hematology, Yeungnam University Medical Center, Korea
[5]Department of Hematology, Hallym University Sacred Heart Hospital, Korea
[6]Department of Hematology, Ewha Womans University School of Medicine, Korea
[7]Department of Hematology, Busan Paik Hospital, Korea
[8]Department of Hematology, Keimyung University, School of Medicine, Keimyung University Hospital, Korea
[9]Department of Hematology, Gachon University Gil Medical Center, Korea
[10]Department of Hematology, Severance Hospital, Yonsei University College of Medicine, Korea

POSTER LIST

PP07-6 **Epidemiological characteristics of multiple myeloma and comorbidity-based model predicting for development of multiple myeloma**

Suein Choi[1], Suenghoon Han[1], Sung-Soo Park[2*] and Chang-Ki Min[2]
[1]*Department of Pharmacology, College of Medicine, The Catholic University of Korea, Korea*
[2]*Department of Hematology, Seoul St.Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Korea*

PP07-7 **Development of multiple myeloma treatment using apoptosis multi-protein target tetracyclic triterpene compound**

Hye Ran Kim[1], Young Eun Lee[2,3], Yong Jun Choi[2], Ha Jin Lim[2], Ju Heon Park[2], Jong Hee Shin[2] and Myung Geun Shin[2,3,4*]
[1]*College of Korean Medicine, Dongshin University, Korea*
[2]*Department of Laboratory Medicine, Chonnam National University and Chonnam National University Hwasun Hospital, Korea*
[3]*BioMedical Sciences Graduate Program (BMSGP), Chonnam National University, Korea*
[4]*Department of Research and Development, KBlueBio Inc., Korea*

PP07-10 **Naïve B cell as predictor of early and long-term treatment outcome in post-transplant myeloma patients**

Nupur Das[1], Meetu Dahiya[1], Ritu Gupta[1*], Lalit Kumar[2], Atul Sharma[2] and Om Dutt Sharma[1]
[1]*Laboratory Oncology, BRAIRCH, AIIMS, New Delhi, India*
[2]*Medical Oncology, BRAIRCH, AIIMS, New Delhi, India*

PP07-12 **The role of minimal residual disease evaluation for patients with multiple myeloma**

Sang Eun Yoon[1], Hyun-Young Kim[2], Duck Cho[2], Seok Jin Kim[1] and Kihyun Kim[1]
[1]*Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
[2]*Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea*

POSTER LIST

PP07-14 **Machine learning-based sequential analysis to assist selection of frontline treatment: Bortezomib-melphalan-prednisolone vs lenalidomide-dexamethasone in multiple myeloma**

Sung-Soo Park[1], Jong Cheol Lee[2], Ja Min Byun[3], Kyucheol Choi[4], Kwan Hyun Kim[4], Sungwon Lim[4,5], Young-Woo Jeon[6], Seung-Ah Yahng[7], Seung-Hwan Shin[8], Chang-Ki Min[1] and Jamin Koo[4,5,9*]

[1]*Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea*
[2]*Otorhinolaryngology, GangNeung Asan Hospital, University of Ulsan College of Medicine, Korea*
[3]*Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Korea*
[4]*ImpriMedKorea, Inc., Seoul, Korea*
[5]*ImpriMed, Inc., Palo Alto, USA*
[6]*Hematology, Yeoido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea*
[7]*Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea*
[8]*Hematology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea*
[9]*Chemical Engineering, Hongik University, Korea*

PP07-15 **Multiparameter flow cytometry provides a highly sensitive and informative method for assessment of minimal residual disease in multiple myeloma**

Min-Sun Kwak[1], Jae-Ryong Shim[1], Suji Park[1], Sung-Hyun Kim[2], Ji Hyun Lee[2] and Jin-Yeong Han[1*]

[1]*Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea*
[2]*Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College Of Medicine, Busan, Korea*

PP07-16 **Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma: Impact of trial-fitness and comparison to alternative regimens**

Seunghwan Shin[1], Seoyoung Koo[2], Sungsoo Park[3], Youngwoo Jeon[4], Seungah Yahng[5], Jaeho Yoon[3], Sungeun Lee[3], Byungsik Cho[3], Kiseong Eom[3], Yoojin Kim[3], Seok Lee[3], Heeje Kim[3], Seokgoo Cho[3], Jongwook Lee[3] and Changki Min[3*]

[1]*Hematology, Hematology Institute, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Korea*
[2]*College of Medicine, The Catholic University of Korea, Korea*
[3]*Hematology, Hematology Hospital, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea*
[4]*Hematology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Korea*
[5]*Hematology, Incheon St. Mary's Hospital, The Catholic University of Korea, Korea*

PP07-17 **Insulin signaling-inducible IFITM1 promotes multiple myeloma progression and bortezomib resistance**

Ji-Young Lim[1], Sung-Soo Park[1], Jungyeon Lee[1], Byung-Su Kim[2] and Chang-Ki Min[1*]

[1]*Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea*
[2]*Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea*

POSTER LIST

PP07-18 **Inflammatory factor-based staging system in multiple myeloma in the new agent era: KMM176 study**

Ji Hyun Lee[1], Sung-Hyun Kim[1], Dongyeop Shin[2], Sung-Soo Yoon[2], Ja Min Byun[2], Sung-Hoon Jung[3], Je-Jung Lee[3], Chang-Ki Min[4], Young Rok Do[5], Hyo Jung Kim[6], Byeong Seok Sohn[7], Sung Hwa Bae[8], Gyeong-Won Lee[9], Sungwoo Park[9], Hyun Jung Lee[10], Min Kyoung Kim[11] and Ho Sup Lee[12*]

[1]Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Korea
[2]Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Korea
[3]Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Korea
[4]Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea
[5]Department of Internal Medicine,, Keimyung University School of Medicine, Korea
[6]Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Korea
[7]Division of Hemato-oncology, Department of Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Korea
[8]Department of Internal Medicine, Catholic University of Daegu School of Medicine, Korea
[9]Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Korea
[10]Department of Internal Medicine, Kyung Hee University Medical Center, Korea
[11]Department of Medicine, Yeungnam University College of Medicine, Korea
[12]Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, Korea

PP07-19 **Exploration of clinical implication of liquid biopsy targeting circulating tumor DNA in multiple myeloma and its precursor diseases**

Sung-Soo Park[1], Chang-Ki Min[1*], Ji-Young Lim[1] and Seung-Hyun Jung[2]

[1]Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea
[2]Biochemistry, College of Medicine, The Catholic University of Korea, Korea

PP07-20 **Development of risk model including functional high risk in patients with relapsed/refractory multiple myeloma: Dynamic Risk Model**

Hee Jeong Cho[1], Myung Won Lee[2], Ju-Hyung Kim[1], Dong Won Baek[1], Sang-Kyun Sohn[1], and Joon Ho Moon[1]

[1]Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Korea
[2]Department of Hematology-Oncology, Chungnam National University Hospital, School of Medicine, Chungnam National University, Korea

POSTER LIST

PP08-2 **Myeloproliferative neoplasms with hypereosinophilia and rearrangement PDGFRB gene in children under 2 years old: First case at Vietnam National Children's Hospital**

Huong TM Nguyen[1] and Ha Nguyen[1]
[1]*Clinical Hematology, National Children's Hospital, Viet Nam*

PP08-3 **Incidental abdominal computed tomography findings of patients newly diagnosed with Philadelphia-negative myeloproliferative neoplasm**

Ik-Chan Song[1], Jeong Suk Koh[1], Sora Kang[1], Myung-Won Lee[1], Hyewon Ryu[1], Hyo-Jin Lee[1], Hwan-Jung Yun[1], Seon Young Kim[2], Jeong Eun Lee[3], Kyung Sook Shin[3] and Deog-Yeon Jo[1*]
[1]*Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea*
[2]*Department of Laboratory Medicine, Chungnam National University College of Medicine, Daejeon, Korea*
[3]*Department of Radiology, Chungnam National University College of Medicine, Daejeon, Korea*

PP08-4 **Acquired von Willebrand disease in patients with Philadelphia-negative myeloproliferative neoplasm**

Ik-Chan Song[1], Jeong Suk Koh[1], Sora Kang[1], Myung-Won Lee[1], Hyewon Ryu[1], Hyo-Jin Lee[1], Hwan-Jung Yun[1] and Deog-Yeon Jo[1*]
[1]*Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea*

PP08-5 **Detection of JAK2 V617F mutation in polycythemia vera diagnosis first time in Mongolia**

Tsogjargal Burentogtokh[1], Sarantsetseg Jigjidsuren[1*] and Odgerel Tsogbadrakh[2]
[1]*First Central Hospital of Mongolia, General Laboratory of Clinical Pathology, Mongolia*
[2]*Mongolia-Japan hospital of MNUMS, Hematology department, Mongolia*

PP08-6 **The value of Neutrophil-to-lymphocyte ratio at the diagnosis of myeloproliferative neoplasm**

Seug Yun Yoon[1], Min Jung Kim[1], Min-Young Lee[1], Kyoung Ha Kim[1], Namsu Lee[1] and Jong-Ho Won[1*]
[1]*Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Korea*

PP08-7 **Mortality causes in myeloproliferative neoplasms patients with COVID-19 Infection: A systematic review**

Tohari Masidi Amin[1], Shinta Oktya Wardhani[2] and Anindia Reina Yolanda[3*]
[1]*Internal Medicine Resident, Medical Faculty of Universitas Brawijaya, Malang, Indonesia*
[2]*Hemato-Oncology Divison of Internal Medicine Department, Medical Faculty of Universitas Brawijaya, Malang, Indonesia*
[3]*Emergency Department, Lavalette General Hospital, Malang, Indonesia*

POSTER LIST

PP08-8 **Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia**
Young Hoon Park[1], Sewon Lee[1], Yeung-Chul Mun[1] and Dong Jin Park[2*]
[1]Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea
[2]Department of Laboratory Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea

PP10-1 **Neutrophil - lymphocyte ratio and interferon gamma release assay results**
Pradita Sri Mitasari[1] and Umi Solekhah Intansari[1,2*]
[1]Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
[2]Integrated Clinical Laboratory, Sardjito General Hospital, Yogyakarta, Indonesia

PP10-2 **The diagnostic value of extended complete blood count parameters for determining infection etiology**
Duyen Nguyen Thi[1] and Nghiem Luong Thi[1]
[1]Hematology Department, National Children Hospital, Viet Nam

PP10-3 **A smartphone-based diagnostic platform for detection of abnormal red blood cell in resource–limited settings**
Duangdao Palasuwan[1*] and Attakorn Palasuwan[1]
[1]Oxidation in Red Cell Disorders Research Unit, Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand

PP10-4 **Chronic active epstein-barr virus infection of T/NK Cell type systemic form mimicking classic Hodgkin lymphoma**
Hoang Thien Dang
Histopathology and Cytology, Blood transfusion and Hematology Hospital, Viet Nam

PP10-5 **The clinical application of RNA sequencing and analysis in hematologic malignancies**
Hongkyung Kim[1], Young Kyu Min[1], Yu Jin Park[1], Saeam Shin[1*], Seung-Tae Lee[1] and Jong Rak Choi[1]
[1]Department of Laboratory Medicine, Yonsei University College of Medicine, Korea

PP10-6 **A prospective analysis about the concordance of current tests used for the diagnosis of BM involvement of B-lineage lymphoma with respect to different lymphoma grade: Focused on the fluorescence in situ hybridization lymphoma panel**
Sang Hyuk Park[1], Seulgi Moon[1], Hyerim Kim[1*] and In-Suk Kim[1]
[1]Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea

POSTER LIST

PP10-10 **White blood cell counting of Sysmex XN hematology analyzer in severe leukopenic samples: Comparison between whole blood mode and low white blood cell mode**
Jongho Yi[1], Hanah Kim[1*], Gun-Hyuk Lee[1], Seung-Wan Kim[1] and Mina Hur[1]
[1]Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea

PP10-11 **The first Korean case of transcobalamin II deficiency with a pathogenic variant in the TCN2 Gene**
Ju Hyeong Lee[1], Yoon Hwan Chang[1*], Jee-Soo Lee[1], Kyung Taek Hong[2], Jung Min Ko[2], Hyoung Jin Kang[2], Hyun Kyung Kim[1] and Moon-Woo Seong[1]
[1]Department of Laboratory Medicine, Seoul National University Hospital, Korea
[2]Department of Pediatrics, Seoul National University Children's Hospital, Korea

PP10-12 **Clinical performance of a novel next-generation sequencing-based IGH clonality assay in pediatric B-cell acute lymphoblastic leukemia patients**
Min-Seung Park[1], Hee Young Ju[2], Keon Hee Yoo[2], Hee-Jin Kim[1], Sun-Hee Kim[1], Duck Cho[1] and Hyun-Young Kim[1*]
[1]Department of Laboratory Medicine & Genetics, Samsung Medical Center, Korea
[2]Department of Pediatrics, Samsung Medical Center, Korea

PP10-13 **Effect of refrigeration storage time delay and RNA extract kit difference in RNA-seq data quality of blood EDTA samples**
Jae Won Yun[1*], Ye Eun Yoon[1], Kwang Woo Lee[1], Jae Sook Han[1], Yoon Jeong Yu[1] and Je Hyun Seo[1]
[1]Veterans Health Service Medical Research Institute, Veterans Health Service Medical Center, Korea

PP10-14 **Comparison study of two analysers for routine coagulation tests**
Halimatun Radziah Othman[1], Mohd Zul-fakar Abd Razak[1] and Khoo Bee Ghai Jessy[1]
[1]Department of Clinical Diagnostics Laboratories, Hospital Al Sultan Abdullah UiTM, Malaysia

PP10-15 **HTLV-1 bZIP factor modulates acetylation-dependent functions in cells via suppression of HDAC6**
Takayuki Ohshima[1*] and Risa Mukai[1]
[1]Faculty of Science and Engineering, Tokushima Bunri University, Japan

POSTER LIST

PP10-17 **Ribosomal component RPS4X as a novel modulator of MDM2 stability: interfering to E3 ubiquitin ligases for MDM2 and prevention of proteasome-mediated degradation**

Satsuki Ryu[1], Hiroki Nakashima[1], Yuka Tanaka[1], Yasuhiro Ishihara[2], Takashi Tominaga[1] and Takayuki Ohshima[1,3*]

[1]Faculty of Pharmaceutical Science at Kagawa Campus, Tokushima Bunri University, Japan
[2]Program of Biomedical Science, Graduate School of Integrated Sciences for Life, Hiroshima University, Japan
[3]Faculty of Science and Engineering, Tokushima Bunri University, Japan

PP10-20 **Evaluation of monocyte distribution width as an early marker for diagnosis of sepsis**

JooHeon Park[1*], JulKi Kang[1], Young Jun Choi[1], Hyun Woo Choi[2], Seung Jung Kee[2], Jong Hee Shin[2] and Myung Geun Shin[1]

[1]Department of Laboratory medicine, Chonnam National University Hwasun Hospital, Korea
[2]Department of Laboratory medicine, Chonnam National University Hospital, Korea

PP10-21 **Lower red blood cell distribution width than actual red blood cell anisocytosis from automated hematology analyzer**

Sholhui Park[1], Min-Kyung So[1] and Jungwon Huh[1*]

[1]Department of Laboratory Medicine, Ewha Womans University, College of Medicine, Korea

PP10-22 **A clinical laboratory-oriented targeted RNA-seq system accurately detected various types of gene fusion reported in Philadelphia chromosome-like B-lymphoblastic leukemia**

Yong Jun Choi[1], Ju Heon Park[1], Young Eun Lee[1,2], Ha Jin Lim[1], Ji Hu Jeon[1], Hye Ran Kim[3], Jong Hee Shin[1] and Myung Geun Shin[1,2,4*]

[1]Department of Laboratory Medicine, Chonnam National Univerisity and Chonnam National University Hwasun Hospital, Hwasun, Korea
[2]BioMedical Sciences Graduate Program (BMSGP), Chonnam National Univerisity and Chonnam National University Hwasun Hospital, Hwasun, Korea
[3]College of Korean Medicine, Dongshin University, Naju, Korea
[4]KBlueBio Inc., Hwasun, Korea

PP10-23 **Performance evaluation of a digital morphology analyzer for leukocyte differential count**

Sojin Lee[1], Jaewoo Song[1*], Hongkyung Kim[1] and Saeam Shin[1]

[1]Department of Laboratory Medicine, Yonsei University College of Medicine, Korea

PP11-2 **Spectrum of haemoglobinopathies; A tertiary care hospital experience**

Noorulain Fareed[1], Ghulam Fatima[1], Aisha Mahesar[1] and M. Saeed Quraishy[1]

[1]Hematology, Dow University of Health Sciences, CHK Central Lab Civil Hospital Karachi, Pakistan

POSTER LIST

PP11-4 **microRNA signature in G6PD gene: Novel insight into miRNA based diagnostic approach**

Attakorn Palasuwan
Clinical microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Thailand

PP11-5 **Sustained complement C1s inhibition with sutimlimab in patients with cold agglutinin disease results in continued efficacy in part B of CADENZA Study**

Jung Won Shin[21], Alexander Roth[1*], Sigbjørn Berentsen[2], Wilma Barcellini[3], Shirley D'Sa[4], Bernd Jilma[5], Marc Michel[6], Ilene Weitz[7], Masaki Yamaguchi[8], Jun-ichi Nishimura[9], Josephine M.I. Vos[10], Joan Cid[11], Michael Storek[12], Nancy Wong[13], Ronnie Yoo[14], Jenifer Wang[15], Deepthi S Vagge[16], Marek Wardęcki[19], Frank Shafer[17], Michelle Lee[18] and Catherine M Broome[20]
[1]Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
[2]Blood Diseases, Oncology and Rheumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
[3]UCLH Centre for Waldenström's Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, UK
[4]Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan
[5]Division of Hematology, MedStar Georgetown University Hospital, Washington DC, USA
[6]Head of Internal Medicine Unit, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, UPEC, Créteil, France
[7]Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
[8]Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
[9]Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
[10]Associate Professor of Clinical Medicine, Keck School of Medicine of USC, Los Angeles, USA
[11]Global Medical Rare Blood Disorders, Sanofi, Cambridge, USA
[12]RCTs Post-Hoc Analyses Team, Sanofi, Cambridge, USA
[13]Global Safety, IQVIA, India
[14]GPV Rare Diseases, Sanofi, Paris, France
[15]Immuno Hematology, Sanofi, Bridgewater, USA
[16]Immuno Hematology, Sanofi, Bridgewater, USA
[17]Rare diseases and Rare Blood disorders, Sanofi, Bridgewater, USA
[18]Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway
[19]Rare diseases and Rare Blood disorders, Sanofi, Bridgewater, USA
[20]Department of Hematology, Osaka University Graduate School of Medicine, Japan
[21]PharmD, RPh. Medical Lead, Rare Blood Disorders, Specialty Care, Sanofi, Korea

POSTER LIST

PP11-6 **Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): 2-Year follow-up from the CARDINAL Study**

Jung Won Shin[19], Alexander Röth[1*], Wilma Barcellini[2], Shirley D'Sa[3], Yoshitaka Miyakawa[4], Catherine M Broome[5], Marc Michel[6], David J Kuter[7], Bernd Jilma[8], Tor Henrik Anderson Tvedt[9], Ilene C Weitz[10], Timothee Sourdille[11], Jennifer Wang[12], Deepthi S Vagge[13], Katarina Kralova[14], Frank Shafer[15], Marek Wardecki[16], Michelle Lee[17] and Sigbjørn Berentsen[18]

[1]Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
[2]Blood Diseases, Oncology and Rheumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
[3]UCLH Centre for Waldenström's Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, UK
[4]Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan
[5]Division of Hematology, MedStar Georgetown University Hospital, Washington DC, USA
[6]Head of Internal Medicine Unit, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, UPEC, Créteil, France
[7]Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
[8]Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
[9]Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
[10]Associate Professor of Clinical Medicine, Keck School of Medicine of USC, Los Angeles, USA
[11]Global Medical Rare Blood Disorders, Sanofi, Cambridge, USA
[12]RCTs Post-Hoc Analyses Team, Sanofi, Cambridge, USA
[13]Global Safety, IQVIA, India
[14]GPV Rare Diseases, Sanofi, Paris, France
[15]Immuno Hematology, Sanofi, Bridgewater, USA
[16]Immuno Hematology, Sanofi, Bridgewater, USA
[17]Rare diseases and Rare Blood disorders, Sanofi, Bridgewater, USA
[18]Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway
[19]PharmD, RPh. Medical Lead, Rare Blood Disorders, Specialty Care, Sanofi, Korea

PP11-7 **Unusual type of anemia gravis associated with trilogy of hookworm infection, peptic ulcer, and melena: A rare case**

Winda Atika Sari[1], Maulidi Izzati[1] and Berty Denny Hermawati[1*]

[1]Department of Internal Medicine, Faculty of Medicine of Universitas Sebelas Maret, Surakarta, Indonesia

PP11-8 **Assessment of knowledge, attitude and practices on iron-deficiency anemia among Filipino teens in Laguna, Philippines**

Cherry Ann Garcia-Durante[1,2*] and Estrella San Juan[2]

[1]Nursing, Emilio Aguinaldo College Manila, Philippines
[2]Nursing, University of Perpetual Help - Dr Jose G Tamayo Medical University, Philippines

POSTER LIST

PP11-13 **Hereditary pyropoikilocytosis: A rare and severe form of congenital haemolytic anaemia**
Jian An Boo[1,2]
[1]*Department of Paediatrics, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia*
[2]*Neonatology Unit, Department of Paediatrics, Hospital Sultanah Bahiyah Alor Setar, Malaysia, Hospital Sultanah Bahiyah Alor Setar Kedah, Malaysia*

PP11-14 **Classification of anemia level based on fuzzy c-means algorithm**
Rifaldy Fajar[1*], Siti Nadya[2], Tiwul Wulandari[3] and Nana Indri[1]
[1]*Mathematical Medicine Laboratory, Karlstad University, Sweden*
[2]*Data Management, Cendana Clinic Laboratory, Indonesia*
[3]*Computational Bioloy and Medicine Laboratory, Yogyakarta State University, Indonesia*

PP11-16 **Are the prevalence of stunting height, anemia among women pregnant, undernourishment and GDP percapita influence to prevalence of anemia among children in ASEAN 5**
Putri Ayu
Economics, Andalas University, Indonesia

PP11-17 **Diagnostic yield of targeted next-generation sequencing for pediatric hereditary hemolytic anemia**
Yu Jeong Choi[2], Saeam Shin[2] and Seung-min Han[1*]
[1]*Department of Pediatrics, Yonsei University College of Medicine, Korea*
[2]*Department of Laboratory Medicine, Yonsei University College of Medicine, Korea*

PP11-20 **A delayed manifestation of autoimmune lymphoproliferative syndrome (ALPS)**
Shi Chyn Lim
[1]*Department of Paediatrics, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia, Hospital Sultanah Bahiyah Alor Setar, Kedah, Malaysia*

PP11-24 **TMPRSS6 rs855791 polymorphism and iron deficiency anaemia susceptibility among Asian population: A systematic review and meta-analysis**
Indah Sagitaisna Putri[1*] and Bastomy Eka Rezkita[1]
[1]*Faculty of Medicine, Sebelas Maret University, Indonesia*

PP12-1 **Association of CD16 158F>V gene polymorphisms with risk of idiopathic thrombocytopenic purpura susceptibility: An updated meta-analysis**
Bastomy Eka Rezkita[1,2*] and Steven Irving[3]
[1]*Internal medicine, University of Sebelas Maret, Indonesia*
[2]*General Medicine, University of Muhammadiyah Jember Hospital, Indonesia*
[3]*General Medicine, Ciputra Hospital CitraGarden City, Indonesia*

POSTER LIST

PP12-3 **Cannabinoid receptor 2 signaling: Role in megakaryocyte development and neuro-immune regulation**
Ravi Kumar Gutti
Department of Biochemistry, University of Hyderabad, India

PP12-4 **Evaluation the outcome of primary immune thrombocytopenia purpura (ITP) in children under 2 years old at Vietnam Children's Hospital**
Huong TM Nguyen[1] and Manh Tran[1]
[1]Clinical Hematology, National Children's Hospital, Viet Nam

PP12-5 **Bone marrow resident memory T cells suppress megakaryocyte apoptosis and promote humoral immunity in immune thrombocytopenia**
Anli Liu[1], Qiang Liu[1], Shaoqiu Leng[1], Xiaoyu Zhang[1] and Jun Peng[1*]
[1]Department of Hematology, Qilu Hospital, Shandong University, China

PP12-6 **Performance validation of three scoring systems for the prediction of thrombotic microangiopathy due to severe ADAMTS13 deficiency and treatment response to therapeutic plasma exchange: The first study in Korea**
Sang Hyuk Park[1], Hyun-Ki Kim[1], Joseph Jeong[1], Seon-Ho Lee[1], Yoo Jin Lee[2], Yoo Jin Kim[2], Jae-Cheol Jo[2] and Ji-Hun Lim[1*]
[1]Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea
[2]Hematology and Cellular Therapy, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea

PP12-7 **Investigation of the immunomodulatory effect of bitter taste receptor on CD4+ T cells in immune thrombocytopenia**
Xiaoyu Zhang
Department of hematology, Qilu Hospital of Shandong University, China

PP12-9 **Eltrombopag plays an anti-viral role by elevated function of exhausted T cells**
Yuefen Hu[1], Shuqian Xu[1] and Jun Peng[1*]
[1]Department of Hematology, Qilu Hospital of Shandong university, Cheeloo College of Medicine, Jinan, China

PP12-10 **Predictive value of high ICAM-1 level for poor treatment response in corticosteroid-resistant immune thrombocytopenia patients**
Li Chaoyang
Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, China

POSTER LIST

PP12-11 **Correlation between HDAC3 rs2530223 polymorphism and the susceptibility or severity of ITP**

Ruxia Zhao
Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China

PP12-12 **The association between nutritional status and platelet count among pediatric patients with dengue hemorrhagic fever in Pekalongan City, Indonesia**

Nisrina Nabila[1*] and Irena Agustiningtyas[2], Nur Aini Djunet[3]
[1]*Medical Student, Universitas Islam Indonesia, Indonesia*
[2]*Microbiology, Universitas Islam Indonesia, Indonesia*
[3]*Biochemistry, Universitas Islam Indonesia, Indonesia*

PP12-15 **Short chain fatty acid butyrate reprogram macrophage function and phenotype in immune thrombocytopenia via immunoepigenitic pathway**

Qiang Liu[1]
[1]*Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China*

PP12-16 **Management of severe hemophilia A: Low-dose prophylaxis vs on-demand treatment**

Munira Borhany[1*], Rabeea Munawar Ali[1], Madiha Abid[2], Sidra Zafar[2], Rukhshanda Nadeem[3] and Raheel Ahmed[3]
[1]*Clinical Hematology, National Institute of Blood Disease and Bone Marrow Transplantation, Pakistan*
[2]*Research and development, National Institute of Blood Disease and Bone Marrow Transplantation, Pakistan*
[3]*Haemophilia, Haemophilia Welfare Society, Karachi, Pakistan*

PP12-17 **Characteristics of essential thrombocytosis in children-A single institution retrospective study**

Jae Wook Lee[1*], Suejung Jo[1], Jae Won Yoo[1], Seongkoo Kim[1], Pil-Sang Jang[1], Nack-Gyun Chung[1] and Bin Cho[1]
[1]*Division of Pediatric Hematology/Oncology, Department of Pediatrics, College of Medicine, The Catholic University of Korea, Korea*

PP12-18 **Thrombotic thrombocytopenic purpura treatment at the hematology department of Cho Ray Hospital**

Thao Nguyen Van[1], Nhu Cao Thi Bich[1*], Tung Tran Thanh[1], Suong Pho Phuoc[2], Toan Ho Trong[2], Tung Nguyen Khac[1], San Le Thi[1], Minh Nguyen Ngoc[1], Ut Nguyen Thi Be[1] and Trung Thai Minh[1]
[1]*Hematology, Cho Ray Hospital, Viet Nam*
[2]*Laboratory, Cho Ray Hospital, Viet Nam*

POSTER LIST

PP12-20 **Romiplostim in pediatric immune thrombocytopenia: A meta-analytic synthesis**
Md Azharuddin[1*] and Manju Sharma[2]
[1]Pharmaceutical Medicine, Jamia Hamdard, India
[2]Pharmacology, Jamia Hamdard, India

PP12-21 **Klinefelter syndrome identified by multi-gene panel testing by massive parallel sequencing as a risk factor for venous thromboembolism**
JaeJoon Lee[1], Min-Seung Park[1], Hyun-Young Kim[1], Chang-Hun Park[3], Sung-A Chang[2], Sun-Hee Kim[1] and Hee-Jin Kim[1*]
[1]Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea
[2]Division of Cardiology, Department of Internal Medicine, Imaging Center, Heart Stroke & Vascular Institute, Sungkyunkwan University School of Medicine, Samsung Medical Center, Korea
[3]Department of Laboratory Medicine & Genetics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Korea

PP13-1 **Analysis of BK virus infection in children after hematopoietic cell transplantation: A retrospective single-center study**
Ang Wei[1], Yuanfang Jing[1], Maoquan Qin[1*] and Tianyou Wang[1]
[1]Hematology center, Beijing children's hospital, China

PP13-2 **High dose etoposide based chemo-mobilization for autologous stem cell transplantation – Revisited**
Jayachandran Perumal Kalaiyarasi[1*], Nadeem Ahmed[1], Parathan Karunakaran[1], Nikita Mehra[1] and Krishnarathinam Kannan[1]
[1]Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, India

PP13-3 **Autologous stem cell transplantation in relapsed Hodgkin lymphoma – A single centre experience from India**
Mangai Suseela Murugesan[1*], Jayachandran Perumal Kalaiyarasi [1], Nikita Mehra[1], Parathan Karunakaran[1], Venkatraman Radhakrishnan[1], Gangothri Selvarajan[1], Sivasree Kesana[1], Carthikeyan Subramaniam Murali [1], Krishnarathinam Kannan[1] and Sagar Tenali Gnana [1]
[1]Medical Oncology, Cancer Institute (WIA), Chennai, India

POSTER LIST

PP13-4 **Clinical impact of recipient-derived isoagglutinin levels in ABO-incompatible hematopoietic stem cell transplantation**

Minjeong Nam[1], Mina Hur[2*], Hanah Kim[2], Tae-Hwan Lee[2], Gun-Hyuk Lee[2], Sumi Yoon[3], Sung Yong Kim[4] and Mark Hong Lee[4]

[1]Department of Laboratory Medicine, Korea University Anam Hospital, Korea
[2]Department of Laboratory Medicine, Konkuk University School of Medicine, Korea
[3]Department of Laboratory Medicine, Chung-Ang University College of Medicine, Korea
[4]Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University School of Medicine, Korea

PP13-5 **Efficacy and safety of cytokine-induced killer cells infusion after autologous hematopoietic stem cell transplantation: an interim result of investigator's initiated clinical study**

Gi-June Min[1], Seok-Goo Cho[1*], Nayoun Kim[3], Keon-il Im[3], Tong Yoon Kim[2] and Young-Woo Jeon[2]

[1]Department of Hematology, Seoul St. Mary's Hematology Hospital, Korea
[2]Department of Hematology, Yeouido St. Mary's Hematology Hospital, Korea
[3]Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Korea

PP13-6 **Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients**

Bo Kyung Kim[1], Kyung Taek Hong[1], Jung Yoon Choi[1], Hyery Kim[2], Hyun Jin Park[1] and Hyoung Jin Kang[1*]

[1]Department of Pediatrics, Seoul National University College of Medicine, Korea
[2]Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Korea

PP13-7 **Better fitness of body surface area-based dosing of mycophenolate mofetil in pediatric patients undergoing HSCT: A prospective model-informed drug development approach**

Kyung Taek Hong[1], Hyun Jin Park[2], Nayoung Han[3], In-Wha Kim[2], Jung Yoon Choi[1], Jung Mi Oh[2] and Hyoung Jin Kang[1,4*]

[1]Pediatrics, College of Medicine, Seoul National University, Seoul National University Hospital, Korea
[2]College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Korea
[3]College of Pharmacy, Jeju National University, Korea
[4]Wide River Institute of Immunology, Korea

PP13-10 **Role of short tandem repeat (STR) in leukemia patients received allogeneic hematopoietic stem cell transplantation**

Juhyung Kim[1], Hee Jeong Cho[1], Joon Ho Moon[2], Sang Kyun Sohn[1] and Dong Won Baek[2*]

[1]Hematology/Oncology, Kyungpook National University Hospital, Korea
[2]Hematology/Oncology, Kyungpook National University Chilgok Hospital, Korea

POSTER LIST

PP13-11 **A case report of central nervous system autoimmune demyelinating disease following allogenic hematopoietic stem cell transplantation**
Ye eun Oh[1], Jong Hyuk Lee[1], Daehun Kwag[1], Gi-June Min[1], Sung-Soo Park[1], Silvia Park[1], Jae-Ho Yoon[1], Sung-Eun Lee[1], Ki-Seong Eom[1], Yoo-Jin Kim[1], Seok Lee[1], Hee-Je Kim[1], Chang-Ki Min[1], Seok-Goo Cho[1], Jong Wook Lee[1] and Byung-Sik Cho[1*]
[1]Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea

PP13-12 **How the caregiver status could increase the quality of life among elderly after allogeneic-HSCT (allo-HSCT) with dementia status?**
Rosinta Hotmaida Pebrianti Purba
Poverty Alleviation and Community Empowerment, Ministry of National Development Planning, Indonesia

PP14-1 **Bitter receptor agonist denatonium benzoate promotes hematopoietic reconstitution after hematopoietic stem cell transplantation in mice**
Jing Qin[1] and Jun Peng[1*]
[1]Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, China

PP14-2 **Novel mechanism of thrombopoiesis by the human megakaryoblastic leukemia cell lines**
Nuntiporn Nunthanasup[1], Kasem Kulkeaw[2], Attakorn Palasuwan[1] and Duangdao Palasuwan[1*]
[1]Oxidation in Red Cell Disorders Research Unit, Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand
[2]Siriraj Integrative Center for Neglected Parasitic Diseases, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

PP14-4 **Telomere shortening in survivors of childhood hematologic malignancies**
Meerim Park[1], Hye-Young Jin[1], Jun Ah Lee[1], Myung-Shin Kim[2] and Hyeon Jin Park[1*]
[1]Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Korea
[2]Departmant of Laboratory Medicine, Seoul St. Mary's Hospital, College of medicine, The Catholic University of Korea, Korea

PP14-5 **Clonal hematopoiesis: Somatic mutations in blood cells from patients with acute ischemic stroke**
Jin-Yeong Han[1*], Suji Park[1], Jae-Ryong Shim[1], Min-Sun Kwak[1], Ji-Hyun Lee[2], Sung-Hyun Kim[2] and Dae-Hyun Kim[3]
[1]Department of Laboratory Medicine, Dong-A University College of Medicine, Korea
[2]Department of Hemato-oncology, Dong-A University College of Medicine, Korea
[3]Department of Neurology, Dong-A University College of Medicine, Korea

POSTER LIST

PP16-1 **Analysis of blood product and laboratory resource wastage due to non-severe allergic transfusion reaction**

Anila Rashid[1*], Hasan Hayat[1], Hareem Alam[1] and Qadeer Ahmed[1]
[1]Haematology & Transfusion Medicine, Aga Khan University Hospital, Pakistan

PP16-2 **Platelet transfusion in pediatric intensive care unit patients**

Pradita Sri Mitasari[1], Usi Sukorini[1,2*] and Teguh Triyono[1,3]
[1]Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
[2]Integrated Clinical Laboratory, Sardjito General Hospital, Yogyakarta, Indonesia
[3]Blood Bank and Transfusion Unit, Sardjito General Hospital, Yogyakarta, Indonesia

PP16-3 **The effect of premedication in transfusion reaction : Systematic review and meta-analysis**

Steven Irving[1,2*] and Bastomy Eka Rezkita[1,3]
[1]Faculty of Medicine, University of Sebelas Maret, Indonesia
[2]General Medicine, Ciputra Hospital CitraGarden City, Indonesia
[3]General Medicine, University of Muhammadiyah Jember Hospital, Indonesia

PP16-4 **Variables affecting immunogenicity of blood group antigens: reflections on the formula calculating immunogenicity**

Yousun Chung[1], Han Joo Kim[2], Hyungsuk Kim[3], Sang-Hyun Hwang[2], Heung-Bum Oh[2] and Dae-Hyun Ko[2*]
[1]Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Korea
[2]Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Korea
[3]Department of Laboratory Medicine, Seoul National University Hospital, Korea

PP16-5 **Assessment of platelet consumption in malignant blood disorders; Can we develop a rationale way to save platelet?**

Nida Anwar[1*], Naveena Fatima[2], Aisha Jamal[1], Qurat-ul-Ain Rizvi[1], Anum Khalid[2], Laraib Majeed[1] and Tahir Shamsi[1]
[1]Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan
[2]Research and Dvelopment, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan

PP16-6 **Quality of life in transfusion-dependent thalassemia patients in Bihar**

Gireesh Dayma[1*] and Sukrat Sinha[2]
[1]Department of Medicine, Rama Medical College, India
[2]Department of Zoology, Nehru Gram Bharati, India

POSTER LIST

PP16-11 **Successful plasmapheresis for patients with catastrophic antiphospholipid syndrome**
Ninda Devita[1] and Adika Zhulhi Arjana[2*]
[1]Biomedical Sciences Programmes, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Indonesia
[2]Clinical Pathology and Laboratory Medicine, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Indonesia

PP16-13 **Advanced Red Cell Immunohematology for Direct Antiglobulin Test (DAT) In Healthy Blood Donors During COVID-19 Pandemic**
Divya Setya[1] and Ankit Malhotra[2]
[1]Transfusion Medicine, Manipal Hospital Jaipur, India
[2]Hematopathology, Manipal Hospital Jaipur, India

PP17-1 **Predicting hematologic cancer using artificial intelligence**
Jakir Hossain Bhuiyan Masud
Digital Health, Public Health Informatics Foundation, Bangladesh

PP17-5 **Chemotherapy induced thrombocytopenia and its association with coagulopathy; A single centre experience**
Nida Anwar[1*], Nvaeena Fatima[2], Laraib Majeed[2] and Anum Khalid[2]
[1]Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan
[2]Research and Development, National Institute of Blood Diseases and Bone Marrow Transplantation, Pakistan

PP17-6 **Secondary hematological malignancies in sarcoma patients: A single-center retrospective study**
Hong Kyu Jeong[1,2], Chang-Bae Kong[3], Won Seok Song[3], Wan Hyeong Cho[3], Dae Geun Jeon[3], Yoon Jung Jang[2], Sung Hyun Yang[2], Im Il Na[2], Hyo-Rak Lee[2] and Hye Jin Kang[2*]
[1]Hematology and Oncology, Hallym Hospital, Incheon, Korea
[2]Hematology and Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Korea
[3]Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Korea

PP17-10 **Study of agricultural vulnerability to organic compound fungides and herbicides and myeloproliferative neoplasms incidence in rural population in India**
Ankush Kumar[1] and Prachi Mishra[1]
[1]Basic Sciences, DAV, A State University, India

POSTER LIST

PP17-15 **Treatment, outcomes and prognostic factors of patients with prolymphocytic leukemia**
Su-Yeon Bang[1], Daehun Kwag[1], Jong Hyuk Lee[1], Gi-June Min[1], Sung-Soo Park[1], Silvia Park[1], Jae-Ho Yoon[1], Sung-Eun Lee[1], Byung-Sik Cho[1], Yoo-Jin Kim[1], Seok Lee[1], Hee-Je Kim[1], Chang-Ki Min[1], Seok-Goo Cho[1], Jong Wook Lee[1] and Ki-Seong Eom[1*]
[1]Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea

PP17-16 **Combination of red cell distribution width and serum human epididymis secretory protein 4 levels as a predictor of malignant ovarian tumors**
Wankyu Eo[1] and Ki Hyung Kim[2*]
[1]Department of Internal Medicine, Kyung Hee University, Korea
[2]Department of Obstetrics and Gynecology, Pusan National University, Korea

PP17-19 **Empowering communities for anemia prevention: Lesson learnt from Indonesian government program**
Mahyuddin Mahyuddin[1] and Kadriah Kadriah[2]
[1]Sociology, Institute Agama Islam Negeri Parepare, Indonesia
[2]Public Health, Al Asyariah Mandar University, Indonesia

PP17-22 **A meta-analysis of emergency hospital admissions among hematological malignancies**
Meenakshi Mourya
Department of Anesthesia, Safdarjung Hospital, New Delhi, India

PP17-24 **Risks of surgical treatment when appendicitis is diagnosed in hematologic patients**
Ho Seok Seo Seo[1*], Sung-Soo Park[2], Kyoung IL Min[2] and Seung Hyun Lee[1]
[1]Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
[2]Department of Hematology, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP18-3 **Assessment of the quality of life by the SF-36 questionnaire in patients with chronic myeloid leukemia in chronic phase after treatment with imatinib mesylate achieved complete cytogenetic response**
Anh Chau Hong[1], Dung Co Nguyen Phuong[1*], Quyen Nguyen Duong Thao[2] and Hoa Nguyen Thi My[1]
[1]Blood Transfusion Hematology Hospital and Pham Ngoc Thach University of Medicine, Hematologist, Viet Nam
[2]Blood Transfusion Hematology Hospital, Hematologist, Viet Nam

POSTER LIST

PP18-6 **Study of reality and perspectives factors for blood donating motivation among urban population of Delhi, India**

Pardeep Kumar[1*], Ranbir Singh[1] and Vinod Sharma[1]
[1]*Basic and applied sciences, Shri Maha Maya Vaishnav Devi Mandir Research Institute, India*

PP18-8 **Quality of life matters in hematopoietic stem-cell transplantation (HSCT)**

Mega Dwi Septivani
Business Administration, Politeknik Negeri Padang, Indonesia

PP18-9 **Spirituality as an alternative to reduce depression in leukemia patients**

Kadriah Kadriah[1*] and Mahyuddin Mahyuddin[2]
[1]*Public Health, Al Asyariah Mandar University, Indonesia*
[2]*Sociology Department, Institute Agama Islam Negeri Parepare, Indonesia*

MEMO

MEMO

The First STAMP inhibitor[1], SCEMBLIX®

SCEMBLIX® demonstrated superior response rate and favorable tolerability by Specifically Targeting the ABL1 Myristoyl Pocket (STAMP) in BCR-ABL1[1,3]

For Adult with Ph+ CML-CP after 2 or more TKIs

- **SUPERIOR EFFICACY** (vs. bosutinib)
  - Nearly doubled MMR rate (25.5% vs. 13.2%) and higher CCyR[a] (39.8% vs. 16.1%) at Week 24[1]
  - Maintained higher MMR rate (37.6% vs. 15.8%) and CCyR[a] (39.8% vs. 16.1%) at Week 96[4]
- **FAVORABLE TOLERABILITY** (vs. bosutinib)
  - Tolerability profile consisted based on a longer median duration of exposure (23.7 months vs. 7.0 months) at Week 96[4,5]
  - Nearly 4 times lower discontinuation rate due to AEs (7.7% vs. 26.3%)[4]

The median follow-up was 14.9 months (Data cutoff of May 25, 2020)[1].
The median follow-up was 2.3 years (Data cutoff of October 6, 2021)[4].

[a] In patients without CCyR at baseline (SCEMBLIX®, n=103; bosutinib, n=62).

[b] The median duration of exposure (range) by the data cutoff was 23.7 (range, 0.0–46.2) months for SCEMBLIX® and 7.0 (0.2–43.3) months for bosutinib.

Study design[1,2]: In this randomized, open-label, active-controlled, multicenter, phase 3 trial study, eligible patients (n=233) who were ≥ 18 years of age, with CML-CP previously treated with ≥ 2 TKIs were randomized in a 2:1 ratio to receive either SCEMBLIX® 40mg twice daily (n=157) or bosutinib 500mg once daily (n=76). The primary end point was the rate of MMR at week 24. Median follow-up was 14.9 months.

Study design[4]: Adults with CML-CP after ≥2 prior TKIs with intolerance or lack of efficacy were randomized 2:1 to SCEMBLIX® 40 mg twice daily (n=157) or bosutinib 500 mg once daily (n=76), stratified by baseline MCyR status. After a median follow-up of 2.3 years (16.5 months additional follow-up since the primary analysis), updated efficacy and safety results were reported (cutoff: October 6, 2021). The key secondary objective was to compare MMR rate at week 96 on SCEMBLIX® versus bosutinib.

CML, chronic myeloid leukemia; **TKI,** tyrosine kinase inhibitor; **STAMP,** Specifically Targeting the ABL1 Myristoyl Pocket; **Ph+ CML-CP,** Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; **MMR,** major molecular response; **CCyR,** complete cytogenetic response; **CML-CP,** chronic myeloid leukemia in chronic phase; **MCyR,** major cytogenetic response

References 1. Réa D, et al. Blood. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. 2021 Nov 25;138(21):2031-2041. **2.** [셈플릭스정] 식품의약품안전처 의약품통합정보시스템(nedrug.mfds.go.kr) **3.** Manley PW, et al. Leuk Res. 2020 Nov;98:106458. **4.** Hochhaus A, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 Jan 30. Online Published. <doi: 10.1038/s41375-023-01829-9.>

PRODUCT INFORMATION

처방하시기 전 QR 코드 또는 식품의약품안전처 의약품통합정보시스템 (https://nedrug.mfds.go.kr)을 통해 상세 제품정보를 참조하시기 바랍니다.

NOVARTIS

SCEMBLIX® (asciminib) 20 mg, 40 mg tablets

KR2303030004

Vyxeos® Liposomal
44 mg/100 mg Powder for concentrate for solution for infusion
daunorubicin / cytarabine

OPTIMISING

Delivery of daunorubicin and cytarabine to increase efficacy versus conventional chemotherapy**,2

SUPPORTING

High-risk* AML patients with a proven survival benefit over conventional chemotherapy**,3

LAYING THE FOUNDATION
TOWARDS LONG-TERM SURVIVAL IN HIGH-RISK AML*,2,3

TOGETHER LONGER

The **first** dual-drug advanced liposomal formulation[1]

Superior overall survival vs. conventional chemotherapy** in patients with high-risk AML*,2,3

*High-risk AML defined as newly diagnosed t-AML or AML-MRC. **Conventional chemotherapy:7+3/5+2.

References 1. Tolcher AW, Mayer LD. *Future Oncol.* 2018;14(13):1317–1332. **2.** Lancet JE, et al. *J Clin Oncol.* 2018;36(26):2684–2692. **3.** Lancet JE, et al. *Lancet Haematol*. 2021;8(7):e481–e491.

Selected Prescribing Information

전문의약품(희귀)

[제품명] 빅시오스리포좀주 **[원료약품 및 분량]** 1바이알 중 시타라빈 100mg, 다우노루비신 44mg **[효능효과]** 1) 성인에서의 새로 진단받은 치료 관련 급성 골수성 백혈병(t-AML)의 치료 2) 성인에서의 새로 진단받은 급수성형성증 관련 변화를 동반하는 급성 골수성 백혈병(AML-MRC)의 치료 **[용법·용량]** 이 약은 정맥으로만 투여한다. 근육주사, 척수강내주사, 피하주사를 금한다. 이 약은 주입펌프를 이용하여 중심 정맥용 카테터(central venous catheter) 또는 말초삽입형 중심정맥 카테터(peripherally inserted central catheter)를 통해 90분간 정맥주입 한다. 혈관외유출로 인한 조직 괴사가 일어나지 않도록 각별히 주의한다. 이 약 치료는 화학요법 의약품 사용 경험이 있는 의사의 감독 하에 개시하고 모니터링해야 한다. 환자는 메스꺼움과 구토에 대해 전 치치를 받을 수 있다. 이 약을 개시하기 전에 항고요산혈증 약물(예: 알로푸리놀)을 고려해야 한다. 이 약은 다우노루비신 주사제 및 시타라빈 주사제와 다른 용법을 가지므로 다른 다우노루비신 및/또는 시타라빈 함유 제제를 대체할 수 없다. 이 약은 세포독성이 있는 의약품이므로 해당되는 특수 취급 및 폐기절차를 따라야 한다. 이 제품은 1회용이다. 미사용 의약품은 적절한 세포독성물질 취급 절차에 따라 폐기하여야 한다. [투여 전 제품의 조제방법과 투여 방법은 제품정보 원문 참고] **<관해유도요법 투여일정에 관한 권고 | 제품정보 원문 용법·용량 [표1: 투여일정] 참고>** 이 약 다우노루비신 44 mg/m² 및 시타라빈 100 mg/m²을 90분간 정맥투여 시 권장하는 투여일정: • 1차 유도요법 제 1, 3, 5일에 투여 • 필요 시, 2차 유도요법 제 1, 3일에 투여 유도요법 실시 전, 환자의 심기능 평가 및 간기능·신기능에 대한 검사가 수행되어야 한다. 1차 유도요법으로 관해에 도달하지 않은 경우, 질병이 진행되지 않거나 허용할 수 없는 독성이 나타나지 않는 환자에게는 1차 유도요법 종료 후 2-5주 시점에 2차 유도요법을 실시할 수 있다. 1차 유도요법 후 골수를 평가하여 2차 유도요법 실시 필요성을 결정한다. 환자가 이익을 얻는 한, 또는 질병이 진행될 때까지, 최대 2차까지의 유도요법 치료를 지속하여야 한다. **<공고요법 투여일정에 관한 권고 | 제품정보 원문 용법·용량 [표1: 투여일정] 참고>** 표1의 투여일정에서 최초 공고요법은 최종 유도요법 개시 후 5-6주 시점에 투여하여야 한다. 이 약 다우노루비신 29 mg/m² 및 시타라빈 65 mg/m²을 90분간 정맥투여 시 권장하는 투여일정: • 필요 시, 1차 및 2차 공고요법 각각 제 1, 3일에 투여 공고요법 실시 전, 환자의 심기능에 대한 평가 및 전혈구검사, 간기능·신기능에 대한 검사가 수행되어야 한다. 공고요법은 절대호중구수(absolute neutrophil count, ANC)> 500/μL 및 혈소판수> 50,000/μL로 회복되어 관해를 달성하고 허용할 수 없는 독성이 나타나지 않은 환자에서 권장된다. 2차 공고요법은 질병이 진행되지 않고 허용할 수 없는 독성이 나타나지 않은 환자에게 1차 공고요법개시 후 5-6주 시점에 투여할 수 있다. 환자가 이익을 얻는 한, 또는 질병이 진행될 때까지, 최대 2차까지 공고요법 치료를 지속하여야 한다. **<치료 중 용량 조절에 관한 권고>** 환자에게 혈액학적 반응과 독성이 나타나는지 모니터링 해야 한다. 필요하다면, 투여를 연기하거나 영구 중단해야 한다(제품정보 원문 용법 · 용량 [치료 중 용량 조절에 관한 권고] 참고). **<특수환자군>** 신장애 환자, 고령자의 용량 조절에 관하여 제품정보 원문 용법 · 용량 [특수환자군] 참고 **[사용상의주의사항] 1. 경고 •** 다른 다우노루비신 및/또는 시타라빈 함유 제제: 이 약은 다른 다우노루비신 및/또는 시타라빈 함유 제제와 약동학적 특성이 상당히 다르고 권장되는 투여용량과 투여일정 또한 동일하지 않으므로 대체 또는 교환할 수 없다. 투여 오류를 피하기 위해, 투여 전 의약품의 이름과 용량을 확인하여야 한다. • 중증의 골수억제: 치료용량의 이 약을 투여한 환자에서 중증의 골수억제(지명적인 감염과 출혈 포함)가 보고된 바 있다. 이 약 투여 환자에서 중증의 혈소판감소증이 동반된 중대한 또는 치명적인 출혈(지명적인 중추신경계 출혈 포함)이 발생하였다. 이 약으로 치료 시 베이스라인 혈구 수를 평가해야 하며, 환자에게 골수억제로 인한 임상적 합병증이 나타나는지 주의 깊게 모니터링 해야 한다. 이 약의 혈장반감기가 길기 때문에 ANC 및 혈소판 회복 시간이 길어질 수 있으며 추가적인 모니터링이 필요할 수 있다. 중성구감소증이 심각한 시기에는 ANC가 500/μL 이상으로 회복될 때까지 예방적 항생제(항균제, 항바이러스제, 항진균제 포함)를 투여할 수 있다. 골수억제 합병증이 나타날 경우, 항생제, 집락자극인자, 수혈 등의 적절한 보조요법을 실시해야 한다. 혈구 수는 회복될 때까지 정기적으로 모니터링 해야 한다. • 심독성: 안트라사이클린계 치료 시 심독성의 위험은 널리 알려져 있다. 이전에 안트라사이클린계 약물로 치료를 받은 적이 있거나,(이전에 독소루비신이나 다우노루비신 염산염의 권장 최대 누적 투여량을 이미 투여받은 환자 포함), 심장질환을 이미 가지고 있거나,(심기능 장애 포함), 이전에 종격에 방사선요법을 받은 적이 있거나, 심독성 약물을 병용하는 경우, 다우노루비신의 의한 심독성 위험이 증가할 수 있다. 비-리포좀 제제의 다우노루비신의 누적 투여량이 550 mg/m²을 넘으면 치료에 의해 유발되는 울혈성 심부전의 발생이 증가한다. 종격에 방사선요법을 받은 환자에서는 이 상한선이 더 낮아지는 것으로 보인다(400 mg/m²). 이 약 누적 투여량과 심독성 위험 간의 관련성은 아직 밝혀지지 않았다. 이 약 치료에 따른 다우노루비신 누적 노출량이 이래 표에 제시되어 있다[제품정보 원문 사용상의 주의사항 [표2: 이 약 치료 주기별 다우노루비신 누적 노출량] 참고]. 심독성이 증가할 수 있는 위험 인자가 있는 환자에서는 심전도검사(ECG)와 함께 다중게이트 방사성핵종 혈관조영술(multi-gated radionuclide angiography, MUGA) 또는 심초음파 검사(echocardiography, ECHO)를 이용하여 베이스라인 심장 평가를 할 것을 권장한다. 심기능을 면밀히 모니터링해야 한다. 심기능 장애가 있는 환자는 이 약 치료 개시나 지속의 이익이 위험을 상회하지 않는 한 이 약 치료를 중단하여야 한다. • 임신/가임기 여성: 이 약을 투여 받는 동안에는 임신을 피하도록 환자에게 권고해야 한다. 남성 환자와 가임기 여성은 이 약 치료기간 동안, 그리고 최종 투여 후 6개월까지 효과적인 피임법을 사용하여야 한다. **2. 다음 환자에는 투여하지 말 것** 이 약의 활성성분이나 부형제에 중대한 과민성 이력이 있는 환자 **3. 이상반응**(안전성 프로파일 요약 부분 발췌) 가장 흔히 나타난 약물이상반응은 발진을 포함한 과민성(66.9%), 발열성 중성구감소증(63.5%), 부종(52.3%), 설사/장염(49.9%), 점막염증(49.9%), 피로(46.4%), 근골격 통증(44.5%), 복통(36.3%), 식욕감소(33.9%), 기침(33.9%), 두통(32.3%), 오한(31.2%), 부정맥(30.4%), 발열(29.6%), 수면장애(25.1%), 저혈압(23.7%)이었다. 가장 흔히 나타난 중대한 약물이상반응은 감염(58.7%), 심독성(18.7%), 출혈(13.1%)이었다. **[수입·판매자]** ㈜한독, 서울시 강남구 테헤란로 132 **[최종개정일]** 2022-11-30

***보다 자세한 정보는 제품 설명서를 참조하시기 바랍니다.**

빅시오스리포좀주 제품설명서

※ 상세 제품 정보는 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(https://nedrug.mfds.go.kr)을 통해 확인하여 주시기 바랍니다.

KR.DAC2211.03

Jazz Pharmaceuticals
Innovation that performs

(주)한독 서울특별시 강남구 테헤란로 132
TEL 02.527.5114 | **FAX** 02.527.5001 | www.handok.co.kr

HANDOK

for the first-line treatment of adult patients with diffuse large B-cell lymphoma (DLBCL).

POLARIX trial demonstrated that treatment with Pola-R-CHP shows clinically meaningful improvement.[1]

Median follow-up of 28.2 months

6.5%
improvement
in progression-free survival

Pola-R-CHP
76.7%
24 months PFS
(95% CI, 72.7-80.8)

R-CHOP
70.2%
24 months PFS

27%
reduction
in risk of progression, relapse or death[1]
(HR 0.73; p=0.02)

POLIVY® INDICATIONS[2]

- Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone/prednisolone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
- POLIVY in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for haematopoietic stem cell transplant and who have failed at least one prior therapy.

PFS, Progression-free survival CI, Confidence interval

[Study design [1]] International, randomised, double-blind, placebocontrolled, phase III trial. The study compared R-CHOP to R-CHP + Pola from 2017 Nov.14 to 2019 Jun. 27. The trial enrolled 879 patients of previously untreated DLBCL in 23 countries. 440 participants were randomly assigned to receive Pola-RCHP and 439 patients were randomly assigned to receive R-CHOP. Primary endpoint is PFS and secondary endpoints are OS and safety.

[Reference 1. Tilly H, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New Engl J Med 2022:386:351-63. **2.** 폴라이비 제품설명서 Version: Polivy-2022-11-28-1.0

폴라이비®주 (폴라투주맙베도틴) **[원료약품 및 그 분량]** 이 약 1바이알(448.5 mg) 중 유효성분: 폴라투주맙 베도틴 (별규) 140mg, 첨가제(안정화제): 백당 288mg, 기타 첨가제: 수산화나트륨, 숙신산, 폴리소르베이트20. **[성상]** 백색 내지 회백색의 동결건조물이 충전된 무색 바이알의 주사제로서 조제된 용액은 무색 내지 미갈색이고 투명하거나 약간의 유백색을 띈 액상 **[효능·효과]** • 이전에 치료받은 적이 없는 미만성 거대 B세포 림프종(DLBCL) 성인 환자에서 리툭시맙, 시클로포스파미드, 독소루비신 및 프레드니손/프레드니솔론(R-CHP)과 병용투여 • 조혈모세포이식이 적합하지 않고 한 가지 이상의 이전 치료에 실패한 재발성 또는 불응성 미만성 거대 B세포 림프종(DLBCL) 성인 환자에서 벤다무스틴 및 리툭시맙과의 병용요법 **[용법·용량] 미만성 거대 B세포 림프종** • 이전에 치료받은 적이 없는 환자: 이 약은 1.8mg/kg의 용량을 6주기 동안 리툭시맙, 시클로포스파미드, 독소루비신 및 프레드니손/프레드니솔론(R-CHP)과 병용하여 21일 간격으로 정맥 내 투여한다. 이 약과 리툭시맙, 시클로포스파미드 및 독소루비신은 제 1일에 프레드니손/프레드니솔론 투여 후 순서와 무관하게 투여할 수 있다. 프레드니손/프레드니솔론은 각 주기의 제1-5일에 투여한다. 7주기 및 8주기는 리툭시맙 단독요법으로 구성된다. • 재발성 또는 불응성 환자: 이 약은 1.8 mg/kg의 용량을 6주기 동안 벤다무스틴 및 리툭시맙과 병용하여 21일 간격으로 정맥 내 투여한다. 이 약과 벤다무스틴 및 리툭시맙은 각 주기의 제1일에 순서와 무관하게 투여할 수 있다. 이 약을 리툭시맙과 함께 투여 할 때 벤다무스틴의 권장 용량은 제1일 및 제2일에 90 mg/m²/day이다. • 이전에 치료받은 적이 없거나 재발성 또는 불응성 환자: 전투여가 이루어지지 않았다면 이 약 투여 전에 항히스타민제 및 해열제를 전투여한다. 이 약의 최초 용량은 90분 동안 정맥 내 투여해야 한다. 최초 용량 투여 도중 및 최초 용량 투여 완료 후 적어도 90분 이상 동안 주입 관련 반응에 대해 환자 모니터링을 해야 한다. 이전 주입 시 내약성이 양호하였다면 이후 이 약은 30분동안 투여할 수 있으며 투여 도중과 투여 완료 후 30분 이상 환자 모니터링을 해야 한다. 계획된 이 약의 투여가 누락된 경우 가능한 한 빨리 투여해야 하며 투여 간격이 21일이 되도록 투여 일정을 조정해야 한다. **용량 조정** 환자에게 주입 관련 반응이 발생하는 경우 이 약의 주입 속도를 늦추거나 주입을 중단한다. 환자가 생명을 위협하는 반응을 경험한다면 이 약의 투여를 즉시 영구적으로 중단한다. 이 약의 용량은 이전에 치료받은 적이 없는 DLBCL 환자와 재발성 또는 불응성 DLBCL 환자에서 다르게 조정한다(제품설명서 전문 표 1 및 표 2 참조). 말초신경병증 관리를 위한 용량 조정은 제품설명서 전문 표 1을 참조한다. 골수억제 관리를 위한 용량 조정은 제품설명서 전문 표 2를 참조한다. 주입 관련 반응에 대한 용량 조정은 제품설명서 전문 표 3를 참조한다. **[사용상의 주의사항] 1. 경고** 1) 골수억제: 중대한 그리고 중증 호중구감소증 또는 발열성 호중구감소증이 이 약을 투여 받은 환자에서 투여 제1주기 초기부터 보고된 바 있다 (제품설명서 전문 3.이상반응 항 참조). 예방적 G-CSF 투여를 고려해야 한다. 이 약 투여 시 3~4등급 혈소판감소증 또는 빈혈이 발생할 수 있다(제품설명서 전문 3.이상반응 항 참조). 이 약의 투여 전에 전혈구수를 모니터링해야 한다. 3~4등급 호중구감소증 또는 혈소판감소증 환자에게는 보다 빈번한 실험실 수치 모니터링 및 이 약의 투여 연기 또는 중단을 고려해야 한다. 2) 말초신경병증: 말초신경병증이 이 약을 투여받은 환자에서 투여 제1주기부터 보고된 바 있으며 순차적 투여에서 그 위험이 증가하였다 (제품설명서 전문 3.이상반응 항 참조). 기존에 말초신경병증이 있는 환자는 상태 악화를 경험할 수 있다. 이 약 투여에서 보고된 말초신경병증은 주로 감각 말초신경병증이지만 운동 및 감각 운동 말초신경병증도 보고된 바 있다. 감각저하, 지각과민, 지각이상, 감각장애, 신경병성 통증, 작열감, 악화 또는 보행 장애 등의 말초신경병증 증상에 대해 환자 모니터링을 해야 한다. 말초신경병증이 새로 발생하거나 악화된 환자는 이 약 투여를 연기하거나 용량을 감소하거나 투여를 중단할 수 있다. 3) 감염: 폐렴(pneumocystis jirovecii 및 기타 진균성 폐렴 등), 박테리아혈증, 패혈증, 헤르페스 감염 및 거대세포바이러스 감염 등 기회감염을 포함한 중대하거나 생명에 위협적이거나 치명적인 감염이 이 약 투여 환자에서 보고된 바 있다(제품설명서 전문 3.이상반응 항 참조). 이 약 치료 중 박테리아성, 진균성 또는 바이러스성 감염의 징후에 대해 환자를 면밀하게 모니터링하여야 한다. 항감염 예방요법을 고려해야 한다. 중대한 감염이 발생한 환자는 이 약 및 모든 병용 화학요법을 중단해야 한다. 4) 진행성 다초점 백질뇌병증(PML): 이 약 투여 시 PML이 보고된 바 있다(제품설명서 전문 3.약물이상반응 항 참조). PML을 암시하는 신경적, 인지적 또는 행동적 변화 발생이나 악화에 대해 환자를 면밀하게 모니터링하여야 한다. PML이 의심된다면 이 약 및 모든 병용 화학요법을 보류해야 하며 진단이 확인되면 영구 중단해야 한다. 5) 종양 용해 증후군: 종양 부담이 높고 종양이 빠르게 증식되는 환자는 종양 용해 증후군 발생 위험이 높을 수 있다. 이 약 투여 전에 가이드라인에 따른 적절한 조치를 취해야 한다. 이 약 투여 중 종양 용해 증후군에 대해 환자를 면밀하게 모니터링하여야 한다. 6) 배태아 독성: 작용 기전 및 비임상 시험 결과에 기초하여 이 약은 임부에게 투여 시 태아에게 유해할 수 있다(제품설명서 전문 6.임부, 수유부, 가임여성에 대한 투여). 임부에게 태아에 대한 위험을 설명하여야 한다. 가임 여성은 이 약 투여 도중 및 마지막 투여 후 9개월 이상 동안 효과적인 피임법을 사용하여야 한다. 가임 여성을 파트너로 둔 남성 환자는 이 약 투여 도중 및 마지막 투여 후 6개월 이상 동안 효과적인 피임법을 사용하여야 한다. 7) 간독성: 아미노전이효소 또는 빌리루빈 상승을 포함한 간세포 손상과 일치하는 간독성의 중대한 증례가 이 약 투여 환자에서 발생한 바 있다. 기존에 간 질환을 가지고 있거나, 기저 간효소 수치가 높거나 약물 병용 시 간 손상 위험이 증가할 수 있다. 간효소 및 빌리루빈 수치를 모니터링해야 한다. **2. 다음 환자에는 투여하지 말 것** 이 약의 주성분 또는 첨가제에 알려진 과민증이 있는 환자 **3. 임부, 수유부, 가임여성에 대한 투여** 1) 임부: 모체에 대한 잠재적 유익성이 태아에 대한 잠재적 위험을 초과하지 않는다면 임신 중 이 약의 투여는 권장되지 않는다. 동물 시험과 이 약물의 작용 기전에 기초할 때 이 약은 태아에게 유해한 영향을 미칠 수 있다. 동물 시험에서 모노메틸 오리스타틴 E(MMAE)는 유전독성 및 배태아 독성을 야기하였다.(전문가용 사용상의 주의사항 중 4. 독성시험 정보 참조) 진통 및 분만 중 이 약의 안전한 사용에 대해서는 확립되어 있지 않다. 2) 수유부: 이 약이 사람 모유로 배출되는지 여부는 알려져 있지 않다. 이 약이 모유 생성 또는 모유 내 존재에 미치는 영향을 평가한 연구는 수행된 바 없다. 많은 약물이 모유로 배출되고 이 약으로 인해 수유아에게 중대한 이상반응이 발생할 수 있는 위험성이 있기 때문에 여성은 이 약 투여 중과 마지막 투여 후 적어도 3개월 동안 수유를 중단해야 한다.

*보다 자세한 제품 문의 또는 제품 관련 부작용 보고는 (주)한국로슈(02-3451-3600)로 연락주시기 바랍니다. 가장 최신 제품정보는 ㈜한국로슈 홈페이지(www.roche.co.kr)에서 확인하실 수 있습니다.

Version: Polivy-2022-11-28-1.0

M-KR-00001723

(주)한국로슈 서울특별시 서초구 서초대로 411. GT Tower(East) 빌딩 17층(06615) / Tel 02.3451.3600 / www.roche.co.kr

SPRYCEL®

EVERY MOMENT MATTERS

60세 이상의 환자에도,[1] 동반질환이 있는 환자에도,[2]
SPRYCEL®은 효과적이었습니다!

- 스프라이셀®은 **65세 이상의 CP-CML 환자군**에서도 **높은 CCyR 및 MMR 달성 비율을 보였습니다.**[3]
  (Median treatment duration 17.0 months [IR 11.9-24.2], CCyR 92.3% , MMR 76.9%)
- 스프라이셀®은 **당뇨, 고지혈증, 위장질환과 같은 동반질환이 있는 CP-CML 환자군**에서도 동반질환이 없는 환자군과 비교하여 **CCyR과 MMR 비율에 유의한 차이가 없었습니다.**[2]
  (12-month response rates, With comorbidity : CCyR 83%, MMR 47% / Without comorbidity : CCyR 83%, MMR 44%)
- 스프라이셀®은 **식사와 관계없이 100 mg 1일 1회 1정 용법**으로, 복약 편의성이 높은 CML 치료제입니다.[4]

STUDY DESIGN:
This "real-life" cohort study included 65 chronic phase CML patients older than 65 years (median 75.1) treated frontline with dasatinib in 26 Italian centers from June 2012 to June 2015, investigating toxicity and efficacy. Starting dose was 100 mg/day. Grade 3/4 hematologic and non-hematologic adverse events were reported in 12.3% and 18.5% of patients, respectively. CCyR and MMR were shown in 92.3% and 76.9% of patients, respectively.[1] 519 patients with newly diagnosed chronic phase CML were randomized to either dasatinib 100 mg/day (n=259) or imatinib 400 mg/day (n=260). Patients were analyzed according to the number and type of baseline comorbidity and age. CCyR, MMR and AEs were analyzed.[2]

CCyR, complete cytogenetic response; **CML,** chronic myeloid leukemia; **CP,** Chronic Phase; **MMR,** major molecular response.

REFERENCES 1. Latagliata R, *et al.* Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. *Leukemia research.* 2011;35(9): 1164-1169. 2. Khoury, H. Jean, *et al.* Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial. *Blood.* 2010;116(21):3421. 3. Latagliata R, *et al.* Frontline dasatinib treatment in a "real-life" cohort of patients older than 65 years with chronic myeloid leukemia. *Neoplasia.* 2016;18(9):536-540. 4. 스프라이셀® 허가사항, 식품의약품안전처.

스프라이셀®정 20 mg/50 mg/70 mg/80 mg/100 mg (다사티닙)

[효능·효과] 1) 새로이 진단받은 만성기 필라델피아 염색체 양성 만성골수성백혈병 (Ph+CML) 성인환자의 치료. 2) 이매티닙을 포함한 선행요법에 저항성 또는 불내성을 보이는 만성기, 가속기, 또는 골수성이나 림프구성 모구성발중기의 만성골수성백혈병 (Ph+CML) 성인환자의 치료. 3) 선행요법에 저항성 또는 불내성을 보이는 필라델피아 염색체 양성 급성 림프구성 백혈병 (Ph+ALL) 성인환자의 치료. 4) 만 1세 이상의 만성기 필라델피아 염색체 양성 만성골수성백혈병 (Ph+CML) 소아환자의 치료. 5) 새로이 진단받은 만 1세 이상의 필라델피아 염색체 양성 급성 림프구성 백혈병 (Ph+ALL) 소아환자의 항암화학요법과의 병용요법. **[용법·용량]** 용법용량은 제품설명서 참조 **[사용상의 주의사항]** 다음 환자에게는 투여하지 말 것 1) 이 약의 주성분 또는 다른 성분들에 과민증 환자 2) 이 약은 유당을 함유하고 있으므로, 갈락토오스 불내성 (galactose intolerance), Lapp 유당분해효소 결핍증 (Lapp lactase deficiency) 또는 포도당-갈락토오스 흡수장애 (glucose-galactose malabsorption) 등의 유전적인 문제가 있는 환자에게는 투여하면 안 된다. 다음의 환자에게는 신중히 투여할 것 1) 혈소판 기능을 억제하는 약물 또는 항응고제 처방 환자 2) QTc 연장경험이 있거나 가능성이 있는 환자 3) 간장애 환자 4) 폐동맥 고혈압 환자 5) B형 간염바이러스 재활성화 환자 ※ **제품을 처방하시기 전 제품설명서를 참고하여 주시기 바랍니다.**

스프라이셀®의 전체 제품설명서는 QR코드로 확인 가능합니다!

Bristol Myers Squibb™ 한국BMS제약 | 서울시 강남구 테헤란로 504 해성 1빌딩 12층 TEL: 02-3404-1300 FAX: 02-3404-1330 bms.com/kr

SPRYCEL® dasatinib 100 mg tablets

729-KR-230001 Mar 2023/Mar 2025

pharmacyclics
An AbbVie Company

Janssen
Pharmaceutical Companies of Johnson & Johnson

imbruvica®
(ibrutinib) capsules

For MCL, CLL, SLL, WM, cGVHD Patients

THE FIRST ORAL BTK TARGET AGENT IMBRUVICA[1,2]

IMBRUVICA®(ibrutinib) works differently from chemotherapy by inhibiting Bruton's tyrosine kinase (BTK)[1-4]

- BTK is an important component of the B-cell receptor and cytokine receptor pathways, playing an essential role in regulating B-cell survival and proliferation[2-4]
- IMBRUVICA® is a small molecule that covalently binds to BTK, inhibiting BTK-dependent signaling pathways[1-4]

MCL, mantle cell lymphoma; **CLL,** chronic lymphocytic leukemia; **SLL,** small lymphocytic lymphoma; **WM,** waldenstrom macroglobulinemia; **cGVHD,** chronic graft-versus-host disease.

[References] 1. Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014;10(6):957-967. **2.** Robak T, et al. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers (Basel). 2022;14(3):771. **3.** Hendriks RW, et al. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14(4):219-232. **4.** Imbruvica US Prescribing Information(Revised: Aug, 2022)

IMBRUVICA® caps. 140mg (ibrutinib)

[Composition and Appearance] 1. Composition Each capsule contains 140 mg of ibrutinib **2. Appearance** White opaque, hard capsule. **[Indications] 1. Mantle cell lymphoma (MCL)** monotherapy for the treatment of adult patients with MCL who have received at least one prior therapy **2. Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma(SLL)**. 1) Monotherapy for the treatment of patients with CLL who have received at least one prior therapy 2) Monotherapy for the treatment of patients with previously untreated CLL/SLL (≥65 years old patients with comorbidities) 3) Combination with obinutuzumab for the treatment of patients with previously untreated CLL/SLL (≥65 years old, or <65 years old with comorbidities or high risks) 4) Combination with rituximab for the treatment of adult patients with previously untreated CLL/SLL without comorbidity. **3. Waldenström's macroglobulinemia (WM)** 1) Monotherapy for the treatment of patients with WM who have received at least one prior therapy 2) Combination with rituximab for the treatment of patients with previously untreated WM or patients with WM who have received at least one prior therapy **4. Chronic graft versus host disease (cGVHD)** for the treatment of patients with cGVHD who have received at least one line of systemic therapy **[Dosage and Administration]** IMBRUVICA should be administered orally once daily with a glass of water at approximately the same time each day. The capsules should be swallowed whole with water and should not be opened, broken, or chewed. IMBRUVICA must not be taken with grapefruit juice. IMBRUVICA should continue until disease progression or no longer tolerated by the patient. **1. MCL**: The recommended dose of IMBRUVICA for MCL is 560 mg (four 140 mg capsules) once daily until disease progression or no longer tolerated by the patient. **2. CLL/SLL**: The recommended dose of IMBRUVICA for CLL/SLL is 420 mg (three 140 mg capsules) once daily until disease progression or no longer tolerated by the patient. IMBRUVICA can be administered as a single agent, or in combination with anti-CD20 therapy (rituximab or obinituzumab). When administering IMBRUVICA in combination with anti-CD20 therapy, it is recommended to administer IMBRUVICA prior to anti-CD20 therapy when given on the same day. **3. WM**: The recommended dose of IMBRUVICA for WM is 420 mg (three 140 mg capsules) once daily until disease progression or no longer tolerated by the patient as a single agent or in combination with rituximab. When administering IMBRUVICA in combination with anti-CD20 therapies, it is recommended to administer IMBRUVICA prior to rituximab when given on the same day. **4.cGVHD**: The recommended dose of IMBRUVICA for cGVHD is 420 mg (three 140 mg capsules) once daily until cGVHD progression, recurrence of an underlying malignancy, or until no longer tolerated by the patient. **[Precautions] 1. Contraindication** IMBRUVICA is contraindicated in patients who have known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to ibrutinib or to the excipients in its formulation. **2. General Precautions** 1) Bleeding-related events 2) Leukostasis 3) Splenic rupture 4) Infections 5) Viral reactivation 6) Cytopenias 7) Interstitial lung disease (ILD) 8) Cardiac arrhythmias and cardiac failure 9) Tumor lysis syndrome 10) Non-melanoma skin cancer 11) Hypertension 12) Haemophagocytic lymphohistiocytosis (HLH) **3. Pregnancy, Breast-feeding and Fertility 1) Pregnancy** IMBRUVICA should not be used during pregnancy. Women should avoid becoming pregnant while taking IMBRUVICA and for up to 1 month after ending treatment. **2) Breast-feeding** Breast-feeding should be discontinued during IMBRUVICA treatment **3) Fertility** Men should be advised not to father a child while receiving IMBRUVICA, and for 3 months following completion of treatment. ※ Last updated: July 11, 2022. **[Importer]** Janssen Korea Ltd.

The registration status and approved product labels of IMBRUVICA may not be the same in different countries. Please refer to your local Product Information before prescribing.

CP-303414-220707

KYOWA KIRIN

Romiplate®
Romiplostim

FDA approval TPO-receptor agonist

The Reliable Platelet Producer

11F, Asia Tower,430,Nonhyeon-ro,Gangnam-gu,Seoul,06223,Rep.of Korea
https://www.kyowakirin.com/kr

로미플레이트주 250마이크로그램
(로미플로스팀)

KR98-2203ROM-BI01

ICKSH 2024

2024 KOREAN SOCIETY OF HEMATOLOGY
INTERNATIONAL CONFERENCE
& 65th ANNUAL MEETING

MARCH 28 - 30, 2024
GRAND WALKERHILL HOTEL,
SEOUL, KOREA

See you at ICKSH 2024 again!

The Korean Society of Hematology

ICKSH 2023

2023 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE
& 64th ANNUAL MEETING

The Korean Society of Hematology

ICKSH 2023 Secretariat: [PEOPLE-X] 1F, Haeoreum B/D 16, Yeoksam-ro 17 gil, Yeoksam-dong, Gangnam-gu, Seoul 06246, Korea
Tel. +82-2-566-6031, 6033 Fax. +82-2-566-6087 E-mail. icksh@icksh.org

Supported by SEOUL METROPOLITAN GOVERNMENT KOREA TOURISM ORGANIZATION